UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended January 28, 2024
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ___

Commission file number 000-15451

graphic
 
PHOTRONICS, INC.
(Exact name of registrant as specified in its charter)

Connecticut
 
06-0854886
(State or other jurisdiction of incorporation or organization)
 
(IRS Employer Identification No.)

15 Secor Road, Brookfield, Connecticut
 
06804
(Address of principal executive offices)
 
(Zip Code)

Registrant’s telephone number, including area code
 
(203) 775-9000

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
COMMON
PLAB
NASDAQ Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes   No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes   No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer
Accelerated Filer
Non-Accelerated Filer
Smaller
Reporting Company
Emerging
Growth company



If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes   No

The registrant had 63,353,714 shares of common stock outstanding as of February 29, 2024.



PHOTRONICS, INC.
QUARTERLY REPORT ON FORM 10-Q
January 28, 2024

TABLE OF CONTENTS

 3
   
 4
     
PART I.
FINANCIAL INFORMATION
 

   
Item 1.
 5
     
 
 5
     
 
 6
     
 
 7
     
 
 8
     
 
 9
     
 
 10
     
Item 2.
 24
     
Item 3.
 31
     
Item 4.
 32

   
PART II.
OTHER INFORMATION
 


 
Item 1.
 33


 
Item 1A.
 33


 
Item 2.
 33


 
Item 3.
 33


 
Item 4.
 33


 
Item 5.
 33


 
Item 6.
 35

Glossary of Terms and Acronyms
 
Definitions of certain terms and acronyms that may appear in this report are provided below.
 
 
AMOLED
Active-matrix organic light-emitting diode. A technology used in mobile devices.
 
Application-specific IC
An integrated circuit customized for a particular use, rather than intended for general-purpose use
 
ASC
Accounting Standards Codification
 
ASP
Average Selling Price
 
ASU
Accounting Standards Update
 
DNP
Dai Nippon Printing Co., Ltd.
 
EUV
A wafer lithography technology using the industry standard extreme ultraviolet (EUV) wavelength. EUV photomasks function by selectively reflecting or blocking light, in contrast to conventional photomasks which function by selectively transmitting or blocking light
 
Exchange Act
The Securities Exchange Act of 1934 (as amended)
 
FASB
Financial Accounting Standards Board
 
Form 10-K
Annual Report on Form 10-K
 
Form 10-Q
Quarterly Report on Form 10-Q
 
FPDs
Flat-panel displays, or “displays”
 
Generation
In reference to flat-panel displays, refers to the size range of the underlying substrate to which a photomask is applied. Higher generation (or “G”) numbers represent larger substrates
 
High-end (photomasks)
For IC, photomasks that are 28nm or smaller; for FPD, AMOLED, G10.5+, and LTPS photomasks
 
ICs
Integrated circuits, or semiconductors
 
LIBOR
London Inter-Bank Offered Rate
 
LTPS
Low-Temperature Poly Silicon, a polycrystalline silicon synthesized at relatively low temperatures; polycrystalline silicon in thin-film transistors (TFTs) are used in liquid-crystal display (LCD) flat panels and to drive organic light-emitting diode (OLED) displays
 
MLA
Master Lease Agreement
 
Optical proximity correction
A photolithography enhancement technique applied to compensate for the limitations of light to maintain the edge placement integrity of an original design, imaged onto a silicon wafer, for further processing to an etched pattern.
 
PDMCX
Xiamen American Japan Photronics Mask Co., Ltd., a joint venture of Photronics and DNP
 
Phase-shift photomasks
Photomasks that take advantage of the interference generated by phase differences to improve image resolution in photolithography
 
Pure-play foundry
A company that does not produce a significant volume of IC products of its own design, but rather operates IC fabrication plants dedicated to producing ICs for other companies
 
RMB
Chinese renminbi
 
ROU (assets)
Right-of-use asset
 
SEC
Securities and Exchange Commission
 
Securities Act
The Securities Act of 1933 (as amended)
 
Sputtering
The bombardment of a material with energetic particles to cause microscopic particles of the material to eject from its surface.
 
U.S. GAAP
Accounting principles generally accepted in the United States of America
 
Wafer
A wafer, or silicon wafer, is a thin slice of semiconductor material that, in the fabrication of microelectronics, serves as the substrate for microelectronic devices built in and upon the wafer

Forward-Looking Statements

This Form 10-Q contains forward-looking statements, as defined by the SEC. The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements made by us, or on our behalf. Forward-looking statements are statements other than statements of historical fact, including, without limitation, those statements that include such words as “anticipates”, “believes”, “estimates”, “expects”, “intends”, “may”, “plans”, “predicts”, and similar expressions, and, without limitation, may address our future plans, objectives, goals, strategies, events, or performance, as well as underlying assumptions and other statements that are other than statements of historical facts. On occasion, in other documents filed with the SEC, press releases, conferences, or by other means, we may discuss, publish, disseminate, or otherwise make available, forward-looking statements, including statements contained within Part I, Item 2 – “Management’s Discussion & Analysis of Financial Condition and Results of Operations” of this Form 10-Q.

Forward-looking statements involve risks and uncertainties, which could cause actual results or outcomes to differ materially from those expressed. Our expectations, beliefs, and projections are expressed in good faith and are believed by us to have a reasonable basis, including, without limitation, management’s examination of historical operating trends, information contained in our records, and information we’ve obtained from other parties. However, we can offer no assurance that our expectations, beliefs, or projections will be realized, accomplished, or achieved.

Forward-looking statements within this Form 10-Q speak only as of the date of its filing, and we undertake no obligation to update any such statements to reflect changes in events or circumstances that may subsequently occur. Users of this Form 10-Q are cautioned that various factors may cause actual results to differ materially from those contained in any forward-looking statements found within this Form 10-Q and that they should not place undue reliance on any forward-looking statement. In addition, all forward-looking statements, whether written or oral and whether made by us or on our behalf, are expressly qualified by the risk factors provided in Part I, Item 1A “Risk Factors” of our Form 10-K, as well as any additional risk factors we may provide in Part II, Item 1A of our Quarterly Reports on Form 10-Q.

PART I.
FINANCIAL INFORMATION

Item 1.
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

PHOTRONICS, INC.
Condensed Consolidated Balance Sheets
(in thousands, except per share amounts)
(unaudited)

 
January 28,
2024
   
October 31,
2023
 
ASSETS
           
Current assets:
           
Cash and cash equivalents
 
$
508,518
   
$
499,292
 
Short-term investments
    12,996       12,915  
Accounts receivable, net of allowance of $1,090 in 2024 and $1,099 in 2023
    203,607      
194,927
 
Inventories
   
50,680
     
49,963
 
Other current assets
   
31,876
     
28,353
 
Total current assets
   
807,677
     
785,450
 
                 
Property, plant and equipment, net
   
742,671
     
709,244
 
Deferred income taxes
   
22,223
     
21,297
 
Other assets
   
10,265
     
10,230
 
Total assets
 
$
1,582,836
   
$
1,526,221
 
                 
LIABILITIES AND EQUITY
               
Current liabilities:
               
Current portion of long-term debt
 
$
20,771
   
$
6,621
 
Accounts payable
   
86,925
     
84,024
 
Accrued liabilities
   
77,593
     
94,578
 
Total current liabilities
   
185,289
     
185,223
 
                 
Long-term debt
   
2,655
     
17,998
 
Other liabilities
   
47,838
     
47,391
 
Total liabilities
   
235,782
     
250,612
 
                 
Commitments and contingencies
   
     
 
                 
Equity:
               
Preferred stock, $0.01 par value, 2,000 shares authorized, none issued and outstanding
   
-
     
-
 
Common stock, $0.01 par value, 150,000 shares authorized, 61,746 shares issued and outstanding at January 28, 2024, and 61,310 shares issued and outstanding at October 31, 2023
   
617
     
613
 
Additional paid-in capital
   
502,903
     
502,010
 
Retained earnings
   
587,299
     
561,119
 
Accumulated other comprehensive loss
   
(67,863
)
   
(88,734
)
Total Photronics, Inc. shareholders’ equity
   
1,022,956
     
975,008
 
Noncontrolling interests
   
324,098
     
300,601
 
Total equity
   
1,347,054
     
1,275,609
 
Total liabilities and equity
 
$
1,582,836
   
$
1,526,221
 

See accompanying notes to condensed consolidated financial statements.

PHOTRONICS, INC.
Condensed Consolidated Statements of Income
(in thousands, except per share amounts)
(unaudited)

 
Three Months Ended
 
   
January 28,
2024
   
January 29,
2023
 
Revenue
 
$
216,334
   
$
211,090
 
Cost of goods sold
   
137,079
     
135,013
 
Gross profit
   
79,255
     
76,077
 
                 
Operating expenses:
               
Selling, general, and administrative
   
18,321
     
16,818
 
Research and development
   
3,445
     
3,302
 
Total operating expenses
   
21,766
     
20,120
 
Operating income
   
57,489
     
55,957
 
 
               
Other income (expense):
               
Foreign currency transactions impact, net
   
(8,908
)
   
(16,944
)
Interest income and other income, net
   
5,251
     
2,584
 
Interest expense
   
(90
)
   
(65
)
Income before income tax provision
   
53,742
     
41,532
 
                 
Income tax provision
   
14,660
     
12,582
 
                 
Net income
   
39,082
     
28,950
 
                 
Net income attributable to noncontrolling interests
   
12,902
     
14,964
 
                 
Net income attributable to Photronics, Inc. shareholders
 
$
26,180
   
$
13,986
 
                 
Earnings per share:
               
Basic
 
$
0.43
   
$
0.23
 
Diluted
 
$
0.42
   
$
0.23
 
                 
Weighted-average number of common shares outstanding:
               
Basic
   
61,455
     
60,894
 
Diluted
   
62,283
     
61,470
 

See accompanying notes to condensed consolidated financial statements.

PHOTRONICS, INC.
Condensed Consolidated Statements of Comprehensive Income
(in thousands)
(unaudited)

 
Three Months Ended
 
   
January 28,
2024
   
January 29,
2023
 
Net income
 
$
39,082
   
$
28,950
 
                 
Other comprehensive (loss) income, net of tax of $0:
               
Foreign currency translation adjustments
   
31,493
     
90,519
 
Other
   
(27
)
   
(54
)
Net other comprehensive (loss) income
   
31,466
     
90,465
 
                 
Comprehensive income
   
70,548
     
119,415
 
                 
Less: comprehensive income attributable to noncontrolling interests
   
23,497
     
31,393
 
                 
Comprehensive income attributable to Photronics, Inc. shareholders
 
$
47,051
   
$
88,022
 

See accompanying notes to condensed consolidated financial statements.

PHOTRONICS, INC.
Condensed Consolidated Statements of Equity
(in thousands)
(unaudited)

 
Three Months Ended January 28, 2024
 
   
Photronics, Inc. Shareholders
             
         
Additional
   Paid-in
   Capital
   
Retained
   Earnings
   
   Accumulated
   Other
   Comprehensive
   Income (Loss)
   
Non-
   controlling
   Interests
   
Total
Equity
 
   
Common Stock
 
  Shares
    Amount
 
Balance at October 31, 2023
   
61,310
   
$
613
   
$
502,010
   
$
561,119
   
$
(88,734
)
 
$
300,601
   
$
1,275,609
 
                                                         
Net income
   
-
     
-
     
-
     
26,180
     
-
     
12,902
     
39,082
 
Other comprehensive income
   
-
     
-
     
-
     
-
     
20,871
     
10,595
     
31,466
 
Shares issued under equity plans
   
436
     
4
     
(1,680
)
   
-
     
-
     
-
     
(1,676
)
Share-based compensation expense
   
-
     
-
     
2,573
     
-
     
-
     
-
     
2,573
 
                                                         
Balance at January 28, 2024
   
61,746
   
$
617
   
$
502,903
   
$
587,299
   
$
(67,863
)
 
$
324,098
   
$
1,347,054
 

 
Three Months Ended January 29, 2023
 
   
Photronics, Inc. Shareholders
             
         
Additional
Paid-in
Capital
   
Retained
Earnings
   
Accumulated
Other
Comprehensive
Income (Loss)
   
Non-
controlling
Interests
   
Total
Equity
 
    Common Stock
 
  Shares     Amount
 
                                           
Balance at October 31, 2022
   
60,791
   
$
608
   
$
493,741
   
$
435,634
   
$
(98,456
)
 
$
230,562
   
$
1,062,089
 
                                                         
Net income
   
-
     
-
     
-
     
13,986
     
-
     
14,964
     
28,950
 
Other comprehensive income
   
-
     
-
     
-
     
-
     
74,036
     
16,429
     
90,465
 
Shares issued under equity plans
   
311
     
3
     
(608
)
   
-
     
-
     
-
     
(605
)
Share-based compensation expense
   
-
     
-
     
1,821
     
-
     
-
     
-
     
1,821
 
                                                         
Balance at January 29, 2023
   
61,102
   
$
611
   
$
494,954
   
$
449,620
   
$
(24,420
)
 
$
261,955
   
$
1,182,720
 

See accompanying notes to condensed consolidated financial statements.

PHOTRONICS, INC.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)

 
Three Months Ended
 
   
January 28,
2024
   
January 29,
2023
 
             
Cash flows from operating activities:
           
Net income
 
$
39,082
   
$
28,950
 
Adjustments to reconcile net income to net cash provided by operating activities:
               
Depreciation and amortization
   
20,702
     
19,105
 
Share-based compensation
   
2,573
     
1,821
 
Changes in assets and liabilities:
               
Accounts receivable
   
(2,906
)
   
(7,565
)
Inventories
   
409
     
1,705
 
Other current assets
   
(2,844
)
   
(13,060
)
Accounts payable, accrued liabilities, and other
   
(15,508
)
   
(3,276
)
                 
Net cash provided by operating activities
   
41,508
     
27,680
 
                 
Cash flows from investing activities:
               
Purchases of property, plant and equipment
   
(43,314
)
   
(31,097
)
Purchases of available-for-sale debt securities
    (2,436 )     -  
Proceeds from maturities of available-for-sale debt securities
    2,500       -  
Government incentives
   
1,091
     
1,014
 
Other
   
(56
)
   
(87
)
                 
Net cash used in investing activities
   
(42,215
)
   
(30,170
)
                 
Cash flows from financing activities:
               
Repayments of debt
   
(1,194
)
   
(9,218
)
Proceeds from share-based arrangements
   
936
     
672
 
Net settlements of restricted stock awards
   
(2,613
)
   
(1,168
)
                 
Net cash used in financing activities
   
(2,871
)
   
(9,714
)
                 
Effects of exchange rate changes on cash, cash equivalents, and restricted cash
   
13,026
     
27,499
 
                 
Net increase (decrease) in cash, cash equivalents, and restricted cash
   
9,448
     
15,295
 
Cash, cash equivalents, and restricted cash at beginning of period
   
501,867
     
322,409
 
                 
Cash, cash equivalents, and restricted cash at end of period
   
511,315
     
337,704
 
                 
Less: Ending restricted cash     2,797       2,912  
                 
Cash and cash equivalents at end of period   $ 508,518     $ 334,792  
                 
Supplemental disclosure of non-cash information:
               
                 
Accruals for property, plant and equipment purchased during the period
 
$
1,628
   
$
12,031
 

See accompanying notes to condensed consolidated financial statements.

PHOTRONICS, INC.
Notes to Condensed Consolidated Financial Statements
(unaudited)
(in thousands, except share amounts and per share data)

NOTE 1 - BASIS OF FINANCIAL STATEMENT PRESENTATION


Photronics, Inc. (“Photronics”, “the Company”, “we”, “our”, or “us”) is  one of the world’s leading manufacturers of photomasks, which are high-precision photographic quartz or glass plates containing microscopic images of electronic circuits. Photomasks are a key element in the manufacture of ICs and FPDs and are used as masters to transfer circuit patterns onto semiconductor wafers and FPD substrates during the fabrication of ICs, a variety of FPDs and, to a lesser extent, other types of electrical and optical components. We operate eleven manufacturing facilities, which are located in Taiwan (3), Korea, China (2), the United States (3), and Europe (2).


The accompanying unaudited condensed consolidated financial statements (“the financial statements”) have been prepared in accordance with U.S. GAAP for interim financial information, and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for annual financial statements. In the opinion of management, adjustments, all of which are of a normal recurring nature, considered necessary for a fair presentation have been included. The financial statements include the accounts of Photronics, its wholly owned subsidiaries, and the majority-owned subsidiaries, which it controls. All intercompany balances and transactions have been eliminated in consolidation. These financial statements should be read in conjunction with the consolidated financial statements and accompanying notes included in our Form 10-K for the fiscal year ended October 31, 2023, where we discuss and provide additional information about our accounting policies and the methods and assumptions used in our estimates.


The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect amounts reported in them. Our estimates are based on historical experience and on various assumptions that we believe to be reasonable under the facts and circumstances at the time they are made. Subsequent actual results may differ from such estimates. We review these estimates periodically and reflect any effects of revisions in the period in which they are determined.



Our business is typically impacted during the first quarter of our fiscal year by the North American, European, and Asian holiday periods, as some customers reduce their development and buying activities during this period. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the fiscal year ending October 31, 2024.

NOTE 2 - ACCOUNT RECEIVABLES
 
The components of Accounts Receivable at the balance sheet dates are presented below.
 
 
 
January 28,
   
October 31,
 
 
 
2024
   
2023
 
Accounts Receivable
 
$
176,146
   
$
171,433
 
Unbilled Receivable
   
28,551
     
24,593
 
Allowance for Credit Losses
   
(1,090
)
   
(1,099
)
 
 
$
203,607
   
$
194,927
 


NOTE 3 - SHORT-TERM INVESTMENTS



Short-term investments consist of U.S. government securities and are classified as available-for-sale. We classify available-for-sale securities on our consolidated balance sheet as follows:


-
Maturing within three months or less from the date of purchase
Cash and cash equivalents
-
Maturing, as of the date of purchase, more than three months, but
with remaining maturities of less than one year, from the balance sheet date
Short-term investments
-
Maturing one year or more from the balance sheet date
Long-term marketable investments


       As of January 28, 2024, all of our available-for-sale securities had, at their dates of purchase, remaining maturities of more than three months, but less than one year, and have been classified as Short-term investments.



Available-for-sale debt investments are reported at fair value, with unrealized gains or losses (net of tax) reported in Accumulated other comprehensive income. The fair values of our available-for-sale securities are Level 1 measurements, based on quoted prices from active markets for identical assets. In the event of a sale of an available-for-sale debt investment, we would determine the cost of the investment sold at the specific individual security level and would include any gain or loss in Interest income and other income, net, where we also report periodic interest earned and the amortization (accretion) of discounts (premiums) related to these investments. The table below provides information on our available-for-sale debt securities.


   
January 28, 2024
   
October 31, 2023
 
   
Amortized
Cost
   
Unrealized
Gains
   
Unrealized
Losses
   
Carrying
Value
   
Amortized
Cost
   
Unrealized
Gains
   
Unrealized
Losses
   
Carrying
Value
 
Government securities
 
$
12,994
   
$
3
   
$
(1
)
 
$
12,996
   
$
12,913
   
$
4
   
$
(2
)
 
$
12,915
 

NOTE 4 - INVENTORIES


Inventories are stated at the lower of cost, determined under the first-in, first-out (“FIFO”) method, or net realizable value. Presented below are the components of Inventories at the balance sheet dates.

 
January 28,
2024
   
October 31,
2023
 
Raw materials
 
$
49,669
   
$
48,948
 
Work in process
   
1,000
     
1,010
 
Finished goods
   
11
     
5
 
   
$
50,680
   
$
49,963
 

NOTE 5 - PROPERTY, PLANT, AND EQUIPMENT, NET


Presented below are the components of Property, plant, and equipment, net at the balance sheet dates.


 
January 28,
2024
   
October 31,
2023
 
Land
 
$
11,537
   
$
11,378
 
Buildings and improvements
   
189,152
     
185,850
 
Machinery and equipment
   
1,968,318
     
1,922,041
 
Leasehold improvements
   
19,572
     
18,894
 
Furniture, fixtures, and office equipment
   
16,985
     
15,856
 
Construction in progress
   
84,356
     
55,434
 
     
2,289,920
     
2,209,453
 
Accumulated depreciation and amortization
   
(1,547,249
)
   
(1,500,209
)
   
$
742,671
   
$
709,244
 


Information on ROU assets resulting from finance leases, at the balance sheet dates, is presented below.

 
 
January 28,
2024
   
October 31,
2023
 
Machinery and equipment
 
$
42,817
   
$
42,820
 
Accumulated amortization
   
(8,351
)
   
(7,655
)
 
 
$
34,466
   
$
35,165
 


The following table presents depreciation expense (including the amortization of ROU assets) related to property, plant, and equipment incurred during the reporting periods.

 
Three Months Ended
 
 
January 28,
2024
 
January 29,
2023
 
Depreciation Expense   $ 20,605     $ 19,028  

NOTE 6 - PDMCX JOINT VENTURE


In January 2018, Photronics, Inc., through its wholly owned Singapore subsidiary (hereinafter, within this Note “we”, “Photronics”, “us”, or “our”), and DNP, through its wholly owned subsidiary “DNP Asia Pacific PTE, Ltd.”, entered into a joint venture under which DNP obtained a 49.99% interest in our IC business in Xiamen, China. The joint venture, which we refer to as “PDMCX”, was established to develop and manufacture photomasks for semiconductors. We entered into this joint venture to enable us to compete more effectively for the merchant photomask business in China, and to benefit from the additional resources and investment that DNP provides to enable us to offer advanced-process technology to our customers.



In 2020, in combination with local financing obtained by PDMCX, Photronics and DNP fulfilled their investment obligations under the PDMCX operating agreement (the Agreement”). As discussed in Note 7, liens were granted to the local financing entity on property, plant, and equipment and were paid off during fiscal year 2023 and there was no remaining debt at October 31, 2023.


Under the Agreement, DNP is afforded, under certain circumstances, the right to put its interest in PDMCX to Photronics. These circumstances include disputes regarding the strategic direction of PDMCX that may arise after the initial two-year term of the Agreement and cannot be resolved between the two parties. As of the date of issuance of these financial statements, DNP had not indicated its intention to exercise this right. In addition, both Photronics and DNP have the option to purchase, or put, their interest from, or to, the other party, should their ownership interest fall below 20.0% for a period of more than six consecutive months. Under all such circumstances, the sales of ownership interests would be at the exiting party’s ownership percentage of the joint venture’s net book value, with closing to take place within three business days of obtaining required approvals and clearance.


The following table presents net income we recorded from the operations of PDMCX during the reporting periods.

   
Three Months Ended
 

 
January 28,
2024
   
January 29,
2023
 
Net income from PDMCX
 
$
6,463
   
$
5,918
 


As required by the guidance in Topic 810 - “Consolidation” of the Accounting Standards Codification (“ASC”), we evaluated our involvement in PDMCX for the purpose of determining whether we should consolidate its results in our financial statements. The initial step of our evaluation was to determine whether PDMCX was a variable interest entity (“VIE”). Due to its lack of sufficient equity at risk to finance its activities without additional subordinated financial support, we determined that it was a VIE. Having made this determination, we then assessed whether we were the primary beneficiary of the VIE and concluded that we were the primary beneficiary during the current and prior year reporting periods; thus, as required, the PDMCX financial results have been consolidated with Photronics. Our conclusion was based on the facts that we held a controlling financial interest in PDMCX (which resulted from our having the power to direct the activities that most significantly impacted its economic performance) and had the obligation to absorb losses and the right to receive benefits that could potentially be significant to PDMCX. Our conclusions that we had the power to direct the activities that most significantly affected the economic performance of PDMCX during the current and prior year reporting periods were based on our right to appoint the majority of its board of directors, which has, among others, the powers to manage the business (through its rights to appoint and evaluate PDMCX’s management), incur indebtedness, enter into agreements and commitments, and acquire and dispose of PDMCX’s assets. In addition, as a result of the 50.01% variable interest we held during the current and prior year periods, we had the obligation to absorb losses, and the right to receive benefits, that could potentially be significant to PDMCX.


The following table presents the carrying amounts of PDMCX assets and liabilities included in our condensed consolidated balance sheets. General creditors of PDMCX do not have recourse to the assets of Photronics (other than the net assets of PDMCX); therefore, our maximum exposure to loss from PDMCX is our interest in the carrying amount of the net assets of the joint venture.


 
January 28,
2024
   
October 31,
2023
 
Classification
 
Carrying
Amount
   
Photronics
Interest
   
Carrying
Amount
   
Photronics
Interest
 
Current assets
 
$
143,250
   
$
71,639
   
$
135,960
   
$
67,994
 
Noncurrent assets
   
150,077
     
75,054
     
136,334
     
68,181
 
Total assets
   
293,327
     
146,693
     
272,294
     
136,175
 
                                 
Current liabilities
   
36,661
     
18,334
     
36,305
     
18,156
 
Noncurrent liabilities
   
1,929
     
965
     
1,873
     
937
 
Total liabilities
   
38,590
     
19,299
     
38,178
     
19,093
 
                                 
Net assets
 
$
254,737
   
$
127,394
   
$
234,116
   
$
117,082
 

NOTE 7 - DEBT


As of January 28, 2024, the Current portion of long-term debt and the Long-term debt balances were comprised of finance leases as described below:

As of January 28, 2024
 
Finance
Leases
 
Principal due:
     
Next 12 months
 
$
20,771
 
Months 13 – 24
 
$
2,632
 
Months 25 – 36
   
12
 
Months 37 – 48
   
11
 
Months 49 – 60
    -  
Long-term debt
   
2,655
 
Total debt
  $ 23,426  
 
       
Interest rate at balance sheet date
    N/A
 
Basis spread on interest rates
   
N/A
 
Interest rate reset
   
N/A
 
Maturity date
    N/A
 
Periodic payment amount     Varies as Lease mature  
Periodic payment frequency
 
Monthly
 
Loan collateral (carrying amount)
 
$
34,466
(1) 

 
(1)
Represents the carrying amount at the balance sheet date of the related ROU assets, in which the lessors have secured interests.


The table below provides information on our long-term debt as of October 31, 2023.

As of October 31, 2023
 
Finance
Leases
 
Principal due:
      
Next 12 months
  $ 6,621  
Months 13 – 24
  $ 17,972  
Months 25 – 36
    12  
Months 37 – 48
    13  
Months 49 – 60
     1
   
Long-term debt
 
17,998  
Total debt
  $ 24,619
 
 
          
Interest rate at balance sheet date
    N/A  
Basis spread on interest rates
    N/A  
Interest rate reset     N/A
 
Maturity date
    N/A
 
Periodic payment amount     Varies as Lease mature  
Periodic payment frequency     Monthly  
Loan collateral (carrying amount)
  $ 35,165 (1)

 
(1)
Represents the carrying amount at the balance sheet date of the related ROU assets, in which the lessors have secured interests.

Finance Leases


In February 2021, we entered into a five-year $7.2 million finance lease for a high-end inspection tool. Monthly payments on the lease, which commenced in February 2021, are $0.1 million per month. Upon the payment of the fiftieth monthly payment and prior to payment of the fifty-first monthly payment, we may exercise an early buyout option to purchase the tool for $2.4 million. If we do not exercise the early buyout option, then at the end of the five-year lease term, the lease shall continue to renew on a month-to-month basis at the same rental terms; at our option, after the original term or any renewal periods, we may return the tool, elect to extend the lease, or purchase the tool at its fair market value. Since we are reasonably certain that we will exercise the early buyout option, our lease liability reflects such exercise and we have classified the lease as a finance lease. The interest rate implicit in the lease is 1.08%.



In December 2020, we entered into a five-year $35.5 million finance lease for a high-end lithography tool. Monthly payments on the lease, which commenced in January 2021, increased from $0.04 million during the first three months to $0.6 million for the following nine months, followed by forty-eight monthly payments of $0.5 million. As of the due date of the forty-eighth monthly payment, we may exercise an early buyout option to purchase the tool for $14.1 million. If we do not exercise the early buyout option, then at the end of the five-year lease term, at our option, we may return the tool, elect to extend the lease term for a period and a lease payment to be agreed with lessor at the time, or purchase the tool for its then-fair market value, as determined by the lessor. Since we are reasonably certain that we will exercise the early buyout option, our lease liability reflects such exercise and we have classified the lease as a finance lease. The interest rate implicit in the lease is 1.58%. The lease agreement incorporates the covenants included in our Credit Agreement, as defined below (expired in September 2023), which are detailed below, and includes a cross-default provision for any agreement or instrument with an outstanding, committed balance greater than $5.0 million in which we are the indebted party.


Corporate Credit Agreement


In September 2018, we entered into a five-year amended and restated credit agreement (the “Credit Agreement”), which had a $50 million borrowing limit, with an expansion capacity to $100 million. The Credit Agreement was secured by substantially all of our assets located in the United States and common stock we own in certain subsidiaries. The Credit Agreement was subject to covenants around minimum interest coverage ratio, total leverage ratio, and minimum unrestricted cash balance (all of which we were in compliance with at the termination of the agreement in September 2023), and limited the amount of cash dividends, distributions, and redemptions we could pay on our common stock to an aggregate annual amount of $50 million. The Credit Agreement expired, and was not renewed as of October 31, 2023.  There were no outstanding borrowings against the Credit Agreement at its expiration.


Xiamen Working Capital Loans


In November 2018, PDMCX obtained approval for revolving, unsecured credit of the equivalent of $25.0 million, pursuant to which PDMCX may enter into separate loan agreements with varying terms to maturity. This facility is subject to annual reviews and extensions, with the most recent extension set to expire in July 2024. In December 2022, we repaid our entire outstanding balance of RMB 25.6 million ($3.6 million). As of January 28, 2024, PDMCX had no amount outstanding against the approval. The interest rates are variable, based on the RMB Loan Prime Rate of the National Interbank Funding Center. Interest incurred on the loans related to the amount borrowed was eligible for reimbursement through incentives provided by the Xiamen Torch Hi-Tech Industrial Development Zone, which provided for such reimbursements up to a prescribed limit and duration.
 
NOTE 8 - REVENUE


We recognize revenue when, or as, control of a good or service transfers to a customer, in an amount that reflects the consideration to which we expect to be entitled in exchange for transferring those goods or services. We account for an arrangement as a revenue contract when each party has approved and is committed to perform under the contract, the rights of the contracting parties regarding the goods or services to be transferred and the payment terms are identifiable, the arrangement has commercial substance, and collection of consideration is probable. Substantially all of our revenue comes from the sales of photomasks. We typically contract with our customers to sell sets of photomasks, which are comprised of multiple layers, the predominance of which we invoice as they ship to customers. As the photomasks are manufactured to customer specifications, they have no alternative use to us and, as our contracts generally provide us with the right to payment for work completed to date, we recognize revenue as we perform, or “over time”, on most of our contracts. We measure our performance to date using an input method, which is based on our estimated costs to complete the various manufacturing phases of a photomask. At the end of a reporting period, there are a number of uncompleted revenue contracts on which we have performed; for any such contracts under which we are entitled to be compensated for our costs incurred plus a reasonable profit, we recognize revenue and a corresponding contract asset for such performance. We account for shipping and handling activities that we perform after a customer obtains control of a good as being activities to fulfill our promise to transfer the good to the customer, rather than as promised services, or performance obligations, under the contract. We report our revenue net of any sales or similar taxes we collect on behalf of government entities.

As stated above, photomasks are manufactured to customer specifications in accordance with their proprietary designs; thus, they are individually unique. Due to their uniqueness and other factors, their transaction prices are individually established through negotiations with customers; consequently, our photomasks do not have standard or “list” prices. The transaction prices of the vast majority of our revenue contracts include only fixed amounts of consideration. In certain instances, such as when we offer a customer an early payment discount, an estimate of variable consideration would be included in the transaction price, but only to the extent that a significant reversal of revenue would not occur when the uncertainty related to the variability was resolved.

Contract Assets, Contract Liabilities, and Accounts Receivable

We recognize a contract asset when our performance under a contract precedes our receipt of consideration from a customer, or before payment is due, and our receipt of consideration is conditional upon factors other than the passage of time. Contract assets reflect our transfer of control of photomasks that are in process or completed but not yet shipped to customers. A receivable is recognized when we have an unconditional right to payment for our performance, which generally occurs when we ship the photomasks. Our contract assets primarily consist of a significant amount of our in-process production orders and fully manufactured photomasks which have not yet shipped, for which we have an enforceable right to collect consideration (including a reasonable profit) in the event the in-process orders are cancelled by customers. On an individual contract basis, we net contract assets with contract liabilities (deferred revenue) for financial reporting purposes. We did not identify impairment indicators for any outstanding contract assets during the three-month periods ended January 28, 2024, or January 29, 2023.


The following table provides information about our contract balances at the balance sheet dates.


Classification
 
January 28,
2024
   
October 31,
2023
 
Contract Assets            
Other current assets
 
$
12,376
    $
10,984
 
                 
Contract Liabilities
               
Accrued liabilities
  $ 8,968
    $ 9,965  
Other liabilities
    11,820
      12,454
 
    $ 20,788     $ 22,419  


The following table presents revenue recognized from contract liabilities that existed at the beginning of the reporting periods.

 
Three Months Ended
 
 
 
January 28,
2024
   
January 29,
2023
 
Revenue recognized from beginning liability
 
$
5,507
   
$
7,638
 


We generally record our accounts receivable at their billed amounts. All outstanding past due customer invoices are reviewed for collectability during, and at the end of, every reporting period. To the extent we believe a loss on the collection of a customer invoice is probable, we record the loss and credit an allowance for credit losses. In the event that an amount is determined to be uncollectible, we charge the allowance for credit losses and derecognize the related receivable. We did not incur any credit losses on our accounts receivable during the three-month periods ended January 28, 2024 or January 29, 2023.


Our invoice terms generally range from net-thirty to ninety days, depending on both the geographic market in which the transaction occurs and our payment agreements with specific customers. In the event that our evaluation of a customer’s business prospects, and financial condition indicate that the customer presents a collectability risk, we modify terms of sale, which may require payment in advance of performance. At the time of adoption, we elected the practical expedient allowed under ASC Topic 606 “Revenue from Contracts with Customers” (“Topic 606”) that permits us not to adjust a contract’s promised amount of consideration to reflect a financing component when the period between when we transfer control of goods or services to customers and when we are paid is one year or less.

In instances when we are paid in advance of our performance, we record a contract liability and, as allowed under the practical expedient in Topic 606, recognize interest expense only if the period between when we receive payment from the customer and the date when we expect to be entitled to the payment is greater than one year. Historically, advance payments we have received from customers have generally not preceded the completion of our performance obligations by more than one year.

Disaggregation of Revenue


The following tables present our revenue for the three-month periods ended January 28, 2024, and January 29, 2023, disaggregated by product type, geographic origin, and timing of recognition.

 
Three Months Ended
 

 
January 28,
2024
   
January 29,
2023
 
Revenue by Product Type
           
IC
           
High-end
 
$
60,875
   
$
48,003
 
Mainstream
   
96,714
     
108,586
 
Total IC
 
$
157,589
   
$
156,589
 
                 
FPD
               
High-end
 
$
50,616
   
$
45,691
 
Mainstream
   
8,129
     
8,810
 
Total FPD
 
$
58,745
   
$
54,501
 
   
$
216,334
   
$
211,090
 

 
Three Months Ended
 

 
January 28,
2024
   
   January 29,
   2023
 
Revenue by Geographic Origin*
           
Taiwan
 
$
74,965
   
$
75,569
 
China
   
58,137
     
58,932
 
Korea
   
40,335
     
37,832
 
United States
   
32,733
     
29,881
 
Europe
   
9,705
     
8,447
 
Other
   
459
     
429
 
   
$
216,334
   
$
211,090
 

* This table disaggregates revenue by the location in which it was earned.

 
Three Months Ended
 
Revenue by Timing of Recognition
 
January 28,
2024
   
   January 29, 2023
 
Over time
 
$
203,527
   
$
197,164
 
At a point in time
   
12,807
     
13,926
 

 
$
216,334
   
$
211,090
 

Contract Costs


We pay commissions to third-party sales agents for certain sales they procure on our behalf. However, the bases of the commissions are the transaction prices of the sales, which are completed in less than one year; thus, no relationship is established with a customer that will result in future business. Therefore, we do not recognize any portion of these sales commissions as costs of obtaining a contract, nor do we currently foresee other circumstances under which we would recognize contract obtainment costs as assets.

Remaining Performance Obligations


As we are typically required to fulfill customer orders within a short period of time, our backlog of orders has historically been two to three weeks for FPD photomasks and one to two weeks for IC photomasks. However, the demand for some IC photomasks has expanded beyond the industrys capacity to supply them within the traditional time period; thus, the backlog, in some cases, can expand to as long as two to three months. As allowed under Topic 606, we have elected not to disclose our remaining performance obligations, which represent the costs associated with the completion of the manufacturing process of in-process photomasks related to contracts that have an original duration of one year or less.

Product Warranties


Our photomasks are sold under warranties that generally range from one to twenty-four months. We warrant that our photomasks conform to customer specifications and will typically repair, replace, or issue a refund for any photomasks that fail to do so. The warranties do not represent separate performance obligations in our revenue contracts. Historically, customer claims under warranties have been immaterial.

NOTE 9 - SHARE-BASED COMPENSATION


In March 2016, shareholders approved our current equity incentive compensation plan (the “Plan”), under which incentive stock options, non-qualified stock options, stock grants, stock-based awards, restricted stock, restricted stock units, stock appreciation rights, performance units, performance stock, and other stock or cash awards may be granted. Shares to be issued under the Plan may be authorized and unissued shares, issued shares that have been reacquired by us (in the open market or in private transactions), or a combination thereof. The maximum number of shares of common stock approved that may be issued under the Plan was four million shares. On March 16, 2023, at its annual meeting of shareholders, the shareholders of Photronics, Inc., approved amendments to the Plan to increase the number of shares available for issuance by an additional one million shares, thereby increasing the shares available for issuance under the Plan from four million to five million. Awards may be granted to officers, employees, directors, consultants, advisors, and independent contractors of Photronics or its subsidiaries. In the event of a change in control (as defined in the Plan), the vesting of awards may be accelerated. The Plan, aspects of which are more fully described below, prohibits further awards from being issued under prior plans. The table below presents information on our share-based compensation expenses for the three-month periods ended January 28, 2024, and January 29, 2023.


    Three Months Ended  
   
January 28,
2024
   
January 29,
2023
 
Expense reported in:
           
Cost of goods sold
 
$
595
   
$
281
 
Selling, general, and administrative
   
1,749
     
1,378
 
Research and development
   
229
     
162
 
Total expense incurred
 
$
2,573
   
$
1,821
 
                 
Expense by award type:
               
Restricted stock awards
 
$
2,573
   
$
1,764
 
Stock options
   
-
     
1
 
Employee stock purchase plan
   
-
     
56
 
Total expense incurred
 
$
2,573
   
$
1,821
 
                 
Income tax benefits of share-based compensation
 
$
99
   
$
155
 
Share-based compensation cost capitalized
 
$
-
   
$
-
 



Restricted Stock Awards



We periodically grant restricted stock awards, the restrictions on which typically lapse over a service period of one to four years. The fair value of the awards is determined on the date of grant, based on the closing price of our common stock. The table below presents information on our restricted stock awards for the three-month periods ended January 28, 2024, and January 29, 2023.


   
Three Months Ended
 
   
January 28,
2024
   
January 29,
2023
 
Number of shares granted in period
   
825,050
     
786,500
 
Weighted-average grant-date fair value of awards (in dollars per share)
 
$
29.77
   
$
16.77
 
Compensation cost not yet recognized
 
$
31,426
   
$
18,526
 
Weighted-average amortization period for cost not yet recognized (in years)
   
3.3
     
3.2
 
Shares outstanding at balance sheet date
   
1,634,315
     
1,374,422
 



Stock Options



Option awards generally vest in one to four years and have a ten-year contractual term. All incentive and non-qualified stock option grants must have an exercise price no less than the market value of the underlying common stock on the date of grant. The grant-date fair values of options are based on closing prices of our common stock on the dates of grant and are calculated using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of our common stock. We use historical option exercise behavior and employee termination data to estimate expected term, which represents the period of time that options are expected to remain outstanding. The risk-free rate of return for the estimated term of an option is based on the U.S. Treasury yield curve in effect at the date of grant. The table below presents information on our stock options for the three-month periods ended January 28, 2024, and January 29, 2023.


   
Three Months Ended
 
   
January 28,
2024
   
January 29,
2023
 
Number of options granted in period
   
-
     
-
 
Cash received from options exercised
 
$
936
   
$
563
 
Compensation cost not yet recognized
 
$
-
   
$
-
 
Weighted-average amortization period for cost not yet recognized (in years)
   
-
     
-
 


Information on outstanding and exercisable option awards as of January 28, 2024, is presented below.

Options
 
Shares
   
Weighted-
Average
Exercise
Price
   
Weighted-
Average
Remaining
Contractual
Life (in years)
   
Aggregate
Intrinsic
Value
 
Outstanding and exercisable at January 28, 2024
   
375,525
   
$
10.31
   

2.59
   
$
7,448
 

NOTE 10 - INCOME TAXES


We calculate our provision for income taxes at the end of each interim reporting period on the basis of an estimated annual effective tax rate adjusted for tax items that are discrete to each period. The table below sets forth the primary reasons that our effective income tax rates differed from the U.S. statutory tax rates in effect during the three-month periods ended January 28, 2024, and January 29, 2023.

Reporting Period
 
U.S. Statutory
Tax Rates
   
Photronics
Effective Tax
Rates
 
Primary Reasons for Differences

 
   
   
Three months ended January 28, 2024
   
21.0%

   
27.3%

Non-recognition of the tax benefit of losses that, in certain jurisdictions, have been offset by valuation allowances; non-U.S. pre-tax income being taxed at higher statutory rates in non-U.S. jurisdictions; and the establishment of uncertain tax positions in non-U.S. jurisdictions.
                      
Three months ended January 29, 2023
   
21.0%

   
30.3%

Non-recognition of the tax benefit of losses that, in certain jurisdictions, have been offset by valuation allowances; non-U.S. pre-tax income being taxed at higher statutory rates in non-U.S. jurisdictions; and the establishment of uncertain tax positions in non-U.S. jurisdictions.



Uncertain Tax Positions


Although the timing of reversal of uncertain tax positions may be uncertain, as they can be dependent upon the settlement of tax audits, we believe that the amount of uncertain tax positions (including interest and penalties, and net of tax benefits) that may be resolved over the next twelve months is immaterial. Resolution of these uncertain tax positions may result from either or both the lapses of statutes of limitations and tax settlements. We are no longer subject to tax authority examinations in the U.S., major foreign, or state tax jurisdictions for years prior to fiscal year 2018. The table below presents information on our unrecognized tax benefits as of the balance sheet dates.

   
January 28,
2024
   
October 31,
2023
 
Unrecognized tax benefits related to uncertain tax positions
 
$
9,744
   
$
8,908
 
Unrecognized tax benefits that, if recognized, would impact the effective tax rate
 
$
9,744
   
$
8,908
 
Accrued interest and penalties related to uncertain tax positions
 
$
688
   
$
576
 

NOTE 11 - EARNINGS PER SHARE


The calculations of basic and diluted earnings per share are presented below.

 
Three Months Ended
 
   
January 28,
2024
   
January 29,
2023
 
Net income attributable to Photronics, Inc. shareholders
 
$
26,180
   
$
13,986
 
Effect of dilutive securities
   
-
     
-
 
Earnings used for diluted earnings per share
 
$
26,180
   
$
13,986
 
                 
Weighted-average common shares computations:
               
Weighted-average common shares used for basic earnings per share
   
61,455
     
60,894
 
Effect of dilutive securities:
               
Share-based payment awards
   
828
     
576
 
Potentially dilutive common shares
   
828
     
576
 
                 
Weighted-average common shares used for diluted earnings per share
   
62,283
     
61,470
 
                 
Basic earnings per share
 
$
0.43
   
$
0.23
 
Diluted earnings per share
 
$
0.42
   
$
0.23
 


The table below illustrates the outstanding weighted-average share-based payment awards that were excluded from the calculation of diluted earnings per share because their exercise price exceeded the average market value of the common shares for the period or, under application of the treasury stock method, they were otherwise determined to be antidilutive.

 
Three Months Ended
 
   
January 28,
2024
   
January 29,
2023
 
Share-based payment awards
   
241
     
268
 
Total potentially dilutive shares excluded
   
241
     
268
 

NOTE 12 - COMMITMENTS AND CONTINGENCIES


As of January 28, 2024, we had commitments outstanding for capital expenditures of approximately $142.2 million, primarily for purchases of high-end equipment.


In May 2022, we were informed of a customs audit in one of our China operations. We estimated a contingency ranging from $2.2 million to $3.7 million, which included unpaid additional customs duties and related interest and penalties for the previous three years (the period under audit). In the three-month period ended May 1, 2022, we recorded a contingent loss of $2.2 million, as we believed this was the most likely outcome. The $2.2 million amount was recorded with a charge to Cost of goods sold in the condensed consolidated statements of income and Accrued liabilities in the condensed consolidated balance sheets. In November 2022, upon settlement of the audit, we reversed $1.0 million of the accrual.


We are subject to various other claims that arise in the ordinary course of business. We believe that our potential liability under such claims, individually or in the aggregate, will not have a material effect on our consolidated financial statements.

NOTE 13 - CHANGES IN ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME BY COMPONENT


The following tables set forth the changes in our accumulated other comprehensive (loss) income by component (net of tax of $0) for the three-month periods ended January 28, 2024, and January 29, 2023.

 
Three Months Ended January 28, 2024
 
   
Foreign Currency
Translation
Adjustments
   
Other
   
Total
 
                   
Balance at October 31, 2023
 
$
(88,044
)
 
$
(690
)
 
$
(88,734
)
Other comprehensive (loss) income
   
31,493
     
(27
)
   
31,466
 
Other comprehensive (loss) income attributable to noncontrolling interests
   
(10,609
)
   
14
     
(10,595
)
                         
Balance at January 28, 2024
 
$
(67,160
)
 
$
(703
)
 
$
(67,863
)


 
Three Months Ended January 29, 2023
 
   
Foreign Currency
Translation
Adjustments
   
Other
   
Total
 
                   
Balance at October 31, 2022
 
$
(97,790
)
 
$
(666
)
 
$
(98,456
)
Other comprehensive (loss) income
   
90,519
     
(54
)
   
90,465
 
Other comprehensive (loss) income attributable to noncontrolling interests
   
(16,466
)
   
37
     
(16,429
)
                         
Balance at January 29, 2023
 
$
(23,737
)
 
$
(683
)
 
$
(24,420
)

NOTE 14 - FAIR VALUE MEASUREMENTS


The accounting framework for determining fair value includes a hierarchy for ranking the quality and reliability of the information used to measure fair value, which enables the reader of the financial statements to assess the inputs used to develop those measurements. The fair value hierarchy consists of three tiers as follows: Level 1, defined as quoted market prices (unadjusted) in active markets for identical securities; Level 2, defined as inputs other than Level 1 that are observable, either directly or indirectly; and Level 3, defined as unobservable inputs that are not corroborated by market data.


The fair values of our cash and certain cash equivalents (Level 1 measurements), accounts receivable, accounts payable, and certain other current assets and current liabilities (Level 2 measurements) approximate their carrying values due to their short-term maturities. The fair values of our Short-term investments are Level 1 measurements. (Please refer to “Investments” within Note 3 for additional fair value information on our Short-term investments.) The fair values of certain cash equivalents are Level 2 measurements that are provided by independent third-party pricing services or other independent entities, which may use matrix pricing, valuation models, or other methods which utilize observable market data. The fair values of our variable-rate debt instruments are Level 2 measurements and approximate their carrying values due to the variable nature of their underlying interest rates. Other than our Short-term investments, we did not have any assets or liabilities measured at fair value, on a recurring or a nonrecurring basis, at January 28, 2024, or October 31, 2023.

NOTE 15 - SHARE REPURCHASE PROGRAMS


In September 2020, the Company’s board of directors authorized the repurchase of up to $100 million of its common stock, pursuant to a repurchase plan under Rule 10b5-1 of the Securities Act. The most recent 10b5-1 plan expired on September 15, 2022, and has not been renewed. Share repurchases under this authorization commenced on September 16, 2020. The repurchase authorization by the Board of Directors has no expiration date, does not obligate us to acquire any common stock, and is subject to market conditions. There have been no shares repurchased for the three-month periods ended January 28, 2024, and January 29, 2023. As of January 28, 2024, $31.7 million was available under this authorization for the purchase of additional shares. All shares repurchased under the program have been retired.

 
NOTE 16 - RECENT ACCOUNTING PRONOUNCEMENTS


Accounting Standards Updates to be Adopted



In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”, to enhance the transparency and decision usefulness of income tax disclosures. The amendments in this update related to the rate reconciliation and income taxes paid disclosures to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. The amendments allow investors to better assess, in their capital allocation decisions, how an entity’s worldwide operations and related tax risks and tax planning and operational opportunities affect its income tax rate and prospects for future cash flows. The guidance in this update will be effective for Photronics in its fiscal year 2026 Form 10-K, with early application of the amendments allowed. We are currently evaluating the effect the adoption of this ASU may have on our disclosures.


In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures”, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance in this update is effective for Photronics in its fiscal year 2025 Form 10-K, with early adoption permitted. We are currently evaluating the effect the adoption of this ASU may have on our disclosures.

Item 2.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
Overview

Management's discussion and analysis (“MD&A”) of the Company's financial condition and results of operations should be read in conjunction with its condensed consolidated financial statements and related notes. Various sections of this MD&A contain forward-looking statements, all of which are presented based on current expectations, which may be adversely affected by uncertainties and risk factors (presented throughout this filing and in the Company's Form 10-K for fiscal year 2023), that may cause actual results to materially differ from these expectations. See “Forward-Looking Statements”.

We sell substantially all of our photomasks to semiconductor designers and manufacturers, and manufacturers of FPDs. Photomask technology is also being applied to the fabrication of other higher-performance electronic products such as photonics, microelectronic mechanical systems, and certain nanotechnology applications. Our selling cycle is tightly interwoven with the development and release of new semiconductor and display designs and applications, particularly as they relate to the semiconductor industry's migration to more advanced product innovation, design methodologies, and fabrication processes. The demand for photomasks primarily depends on design activity rather than sales volumes from products manufactured using photomask technologies. Consequently, an increase in semiconductor or display sales does not necessarily result in a corresponding increase in photomask sales. However, the reduced use of customized ICs, reductions in design complexity, other changes in the technology or methods of manufacturing or designing semiconductors, or a slowdown in the introduction of new semiconductor or display designs could reduce demand for photomasks ‒ even if the demand for semiconductors and displays increases. Advances in semiconductor, display, and photomask design and production methods that shift the burden of achieving device performance away from lithography could also reduce the demand for photomasks. Historically, the microelectronics industry has been volatile, experiencing periodic downturns and slowdowns in design activity. These negative trends have been characterized by, among other things, diminished product demand, excess production capacity, and accelerated erosion of selling prices, with a concomitant effect on revenue and profitability.

We are typically required to fulfill customer orders within a short period of time, sometimes within twenty-four hours. This results in a minimal level of backlog, typically two to three weeks of backlog for FPD photomasks and one to two weeks for IC photomasks. However, the demand for some IC photomasks has expanded beyond the industry’s capacity to supply them within the traditional time period; thus, for some products, the backlog can expand to as long as two to three months.

The global semiconductor and FPD industries are driven by end markets which have been closely tied to consumer-driven applications of high-performance devices, including, but not limited to, mobile display devices, mobile communications, and computing solutions. While we cannot predict the timing of the industry's transition to volume production of next-generation technology nodes, or the timing of up and down-cycles with precise accuracy, we believe that such transitions and cycles will continue into the future, beneficially and adversely affecting our business, financial condition, and operating results as they occur. We believe our ability to remain successful in these environments is dependent upon the achievement of our goals of being a service and technology leader and efficient solutions supplier, which we believe should enable us to continually reinvest in our global infrastructure.

Results of Operations
Three Months Ended January 28, 2024

The following table presents selected operating information expressed as a percentage of revenue. The columns may not foot due to rounding.

   
Three Months Ended
 
   
January 28,
   
October 31,
   
January 29,
 
   
2024
   
2023
   
2023
 
Revenue
   
100.0
%
   
100.0
%
   
100.0
%
Cost of goods sold
   
63.4
     
62.7
     
64.0
 
Gross profit
   
36.6
     
37.3
     
36.0
 
                         
Operating expenses:
                       
Selling, general, and administrative
   
8.5
     
7.4
     
8.0
 
Research and development
   
1.6
     
1.5
     
1.6
 
Operating income
   
26.6
     
28.5
     
26.5
 
                         
Other operating income (expense), net
   
(1.7
)
   
8.2
     
(6.8
)
                         
Income before income tax provision
   
24.8
     
36.7
     
19.7
 
                         
Income tax provision
   
6.8
     
8.9
     
6.0
 
                         
Net income
   
18.1
     
27.8
     
13.7
 
                         
Net income attributable to noncontrolling interests
   
6.0
     
8.2
     
7.1
 
                         
Net income attributable to Photronics, Inc. shareholders
   
12.1
%
   
19.6
%
   
6.6
%

Note: All tabular comparisons included in the following discussion, unless otherwise indicated, are for the three months ended January 28, 2024 (Q1 FY24), October 31, 2023 (Q4 FY23), and January 29, 2023 (Q1 FY23). The columns may not foot due to rounding.

Revenue

 Our quarterly revenues can be affected by the seasonal purchasing practices of our customers. As a result, demand for our products is typically reduced during the first quarter of our fiscal year by the North American, European, and Asian holiday periods, as some of our customers reduce their development and, consequently, their buying activities during those periods.

The following tables present changes in disaggregated revenue in Q1 FY24 from revenue in prior reporting periods.

Quarterly Changes in Revenue by Product Type

   
Q1 FY24 compared with Q4 FY23
   
Q1 FY24 compared with Q1 FY23
 
   
Revenue in
   
Increase
   
Percent
   
Increase
   
Percent
 
   
Q1 FY24
   
(Decrease)
   
Change
   
(Decrease)
   
Change
 
IC
                             
High-end *
 
$
60.9
   
$
3.2
     
5.5
%
 
$
12.9
     
26.8
%
Mainstream
   
96.7
     
(10.1
)
   
(9.4
)%
   
(11.9
)
   
(10.9
)%
                                         
Total IC
 
$
157.6
   
$
(6.9
)
   
(4.2
)%
 
$
1.0
     
0.6
%
                                         
FPD
                                       
High-end *
 
$
50.6
   
$
(2.7
)
   
(5.0
)%
 
$
4.9
     
10.8
%
Mainstream
   
8.1
     
(1.6
)
   
(16.2
)%
   
(0.7
)
   
(7.7
)%
                                         
Total FPD
 
$
58.7
   
$
(4.3
)
   
(6.7
)%
 
$
4.2
     
7.8
%
                                         
Total Revenue
 
$
216.3
   
$
(11.2
)
   
(4.9
)%
 
$
5.2
     
2.5
%

* High-end photomasks typically have higher average selling prices (ASPs) than mainstream products.

Quarterly Changes in Revenue by Geographic Origin**

   
Q1 FY24 compared with Q4 FY23
   
Q1 FY24 compared with Q1 FY23
 
   
Revenue in
   
Increase
   
Percent
   
Increase
   
Percent
 
   
Q1 FY24
   
(Decrease)
   
Change
   
(Decrease)
   
Change
 
Taiwan
 
$
75.0
   
$
(4.3
)
   
(5.5
)%
 
$
(0.6
)
   
(0.8
)%
China
   
58.1
     
(1.1
)
   
(1.8
)%
   
(0.8
)
   
(1.3
)%
Korea
   
40.3
     
(1.9
)
   
(4.4
)%
   
2.5
     
6.6
%
United States
   
32.7
     
(4.1
)
   
(11.1
)%
   
2.8
     
9.5
%
Europe
   
9.7
     
0.4
     
4.4
%
   
1.3
     
14.9
%
Other
   
0.5
     
(0.2
)
   
(34.4
)%
   
-
     
7.0
%
   
$
216.3
   
$
(11.2
)
   
(4.9
)%
 
$
5.2
     
2.5
%

** This table disaggregates revenue by the location in which it was earned.

Revenue in Q1 FY24 was $216.3 million, representing a decrease of 4.9% compared with Q4 FY23 and an increase of 2.5% from Q1 FY23.

IC photomask revenue decreased by 4.2% compared with Q4 FY23. The decrease from Q4 FY 23 was primarily the result of reduced mainstream demand in Asia. IC photomask revenue slightly increased compared to Q1 FY23 with an increase in high end demand offsetting the decrease in mainstream.

FPD revenue decreased 6.7% compared with Q4 FY23. The decrease from Q4 FY23 was due to premium smartphone seasonality. FPD revenue increased 7.8% from Q1 FY23 due to increased high end demand for AMOLED. We believe that strong demand for AMOLED photomasks will continue, as expected technology advances drives increasing overall demand for higher-value masks.

Gross Margin

               
Percent
         
Percent
 
   
Q1 FY24
   
Q4 FY23
   
Change
   
Q1 FY23
   
Change
 
Gross profit
 
$
79.3
   
$
84.9
     
-6.6
%
 
$
76.1
     
4.2
%
Gross margin
   
36.6
%
   
37.3
%
           
36.0
%
       

Gross margin decreased 70 basis points in Q1 FY24, from Q4 FY23. Material costs decreased 5.1% from the prior quarter, and, as a percentage of revenue, by 3 basis points. Labor cost decreased 2.7% from the prior quarter, but, as a percentage of revenue, increased by 27 basis points. Equipment and other overhead costs decreased 3.3% but increased 47 basis points as a percentage of revenue.

Gross margin increased 60 basis points, in Q1 FY24, from Q1 FY23, primarily as a result of the increase in revenue from the prior year quarter and favorable product mix. Material costs increased 2.3% from the prior year quarter, but decreased as a percentage of revenue by 3 basis points. Labor and benefits costs increased 4.1% from the prior year quarter, and increased, as a percent of revenue, by 19 basis points as labor increased in both the U.S. and at several Asia-based facilities, reflecting labor market conditions. Equipment and other overhead costs remained flat but decreased 67 basis points as a percentage of revenue.

Selling, General, and Administrative Expenses

Selling, general, and administrative expenses were $18.3 million in Q1 FY24, compared with $16.7 million in Q4 FY23. The increase of $1.6 million was primarily the result of increased compensation and related expenses of $1.6 million. Selling, general, and administrative expenses increased $1.5 million in Q1 FY24, from $16.8 million in Q1 FY23, primarily as a result of increased compensation and related expenses of $1.4 million.

Research and Development Expenses

Research and development expenses, which primarily consist of development and qualification efforts related to process technologies for high-end IC and FPD applications, were $3.4 million in Q1 FY24, $3.4 million in Q4 FY23, and $3.3 million in Q1 FY23.

Non-operating Income (Expense)

   
Q1 FY24
   
Q4 FY23
   
Q1 FY23
 
Foreign currency transactions impact, net
 
$
(8.9
)
 
$
13.2
   
$
(16.9
)
Interest expense, net
   
(0.1
)
   
(0.1
)
   
(0.1
)
Interest income and other income (expense), net
   
5.3
     
5.6
     
2.6
 
                         
Non-operating income (expense), net
 
$
(3.7
)
 
$
18.7
   
$
(14.4
)

Non-operating income (expense) decreased $22.4 million to $(3.7) million in Q1 FY24, compared with $18.7 million in Q4 FY23, primarily due to foreign currency transactions impact, net, driven by unfavorable movements of New Taiwan Dollar and the South Korean won against the U.S. dollar. Non-operating income (expense) increased $10.7 million from Q1 FY23 compared with $(14.4) million, primarily due to foreign currency transaction impact, net, driven by favorable movements of the South Korean won and RMB against the U.S. dollar.

Interest income and other income (expense), net, of $5.3 million in Q1 FY24 remained flat compared with $5.6 million in Q4 FY23. Interest income and other income (expense), net, increased $2.7 million compared to Q1 FY23 driven by an increase in cash and cash equivalents, and higher interest rates.

Income Tax Provision

   
Q1 FY24
   
Q4 FY23
   
Q1 FY23
 
                   
                   
Income tax provision
 
$
14.7
   
$
20.3
   
$
12.6
 
Effective income tax rate
   
27.3
%
   
24.3
%
   
30.3
%

The effective income tax rate is sensitive to the jurisdictional mix of earnings, due in part to the non-recognition of tax benefits on losses in jurisdictions with valuation allowances where the tax benefits of the losses are not available.

The effective income tax rate increase in Q1 FY24, compared with Q4 FY23, is primarily due to changes in the jurisdictional mix of earnings and an increase in foreign taxes in Q1 FY24.

The effective income tax rate decrease in Q1 FY24, compared with Q1 FY23, is primarily due to changes in the jurisdictional mix of earnings.

Net Income Attributable to Noncontrolling Interests

Net income attributable to noncontrolling interests was $12.9 million in Q1 FY24, compared with $18.5 million in Q4 FY23, and $15.0 million in Q1 FY23. The decrease from Q4 FY23 and Q1 FY23, to Q1 FY24 resulted from decreased net income at our Taiwan-based IC joint venture.

Liquidity and Capital Resources
 
Cash and cash equivalents were $508.5 million and $499.3 million as of January 28, 2024, and October 31, 2023, respectively. As of the most recent balance sheet date, total cash and cash equivalents included $494.0 million held by foreign subsidiaries. Net Cash, a non-GAAP financial measure as defined and discussed in the Non-GAAP Financial Measures section below, was $485.0 million and $474.7 million as of January 28, 2024, and October 31, 2023, respectively. Our primary sources of liquidity are our cash on hand, cash we generate from operations, and borrowing capacity we have available from financial institutions. In China, we currently have approximately $25.0 million of borrowing capacity to support local operations. See Note 7 to the condensed consolidated financial statements for additional information on our outstanding debt and currently available financing.

We continually evaluate alternatives for efficiently funding our capital expenditures and ongoing operations. These reviews may result in our engagement in a variety of investing and financing transactions, in the transfer of cash among subsidiaries, and/or the repatriation of cash to the U.S. The transfer of funds among subsidiaries could be subject to foreign withholding taxes; in certain jurisdictions, repatriation of these funds to the U.S. may subject them to U.S. state income taxes and/or local country withholding taxes. We believe that our liquidity, including available financing, is sufficient to meet our requirements through the next twelve months and thereafter for the foreseeable future. Through the utilization of our existing liquidity, cash we generate from operations, short-term investments, and (potentially) our borrowing capacity under our financing arrangement, we plan to continue to invest in our business, with our investments targeted to align with our customers’ technology road maps. We may also elect to use our cash to reduce our debt through early repayments. In addition, we stand ready to invest in mergers, acquisitions, or strategic partnerships, should a suitable opportunity arise.

    We estimate capital expenditures for full year FY24 will be approximately $140 million; these investments will be targeted towards high-end and mainstream IC capacity and efficiency and enable us to support our customers’ near-term demands. As of January 28, 2024, we had outstanding capital commitments of approximately $142.2 million and recognized liabilities related to capital equipment purchases of approximately $13.9 million. Although payment timing could vary, primarily as a result of the timing of tool delivery, installation, and testing, we currently estimate that we will fund $99.1 million of our total $156.1 million committed and recognized obligations for capital expenditures over the next twelve months.

In September 2020, the Company’s board of directors authorized the repurchase of up to $100 million of its common stock, pursuant to a repurchase plan under Rule 10b5-1 of the Securities Act. This authorization does not obligate the Company to repurchase any dollar amount or number of shares of common stock. The most recent 10b5-1 plan expired on September 15, 2022, and has not been renewed. As of January 28, 2024, our current share repurchase program had approximately $31.7 million remaining under its authorization. Depending on market conditions, we may utilize some or the entire remaining approved amount to reacquire additional shares.
 
As discussed in Note 6 to the condensed consolidated financial statements, DNP, the noncontrolling interest in our China-based joint venture has, under certain circumstances, the right to put its interest in the joint venture to Photronics, or to purchase our interest in the joint venture. Under all such circumstances, the sale of DNP’s interest would be at its ownership percentage of the joint venture’s net book value, with closing to take place within three business days of obtaining required approvals and clearance. As of the date of issuance of this report, DNP had not indicated its intention to exercise this right. As of January 28, 2024, Photronics and DNP each had net investments in this joint venture of approximately $127.4 million.

Cash Flows

   
Q1 FY24
   
Q1 FY23
 
Net cash provided by operating activities
 
$
41.5
   
$
27.7
 
Net cash used in investing activities
 
$
(42.2
)
 
$
(30.2
)
Net cash used in financing activities
 
$
(2.9
)
 
$
(9.7
)

Operating Activities: Net cash provided by operating activities reflects net income adjusted for certain non-cash items, including depreciation and amortization, share-based compensation, and the impacts of cash from changes in operating assets and liabilities. Net cash provided by operating activities increased $13.8 million in Q1 FY24, compared with Q1 FY23.

Free Cash Flow which is non-GAAP financial measure as discussed in the “Non-GAAP Financial Measures” section below, increased by $1.6 million, compared with Q1 FY23, primarily due to the increase in net cash provided by operating activities, partially offset by the increase in purchases of property, plant, and equipment.

Investing Activities: Net cash flows used in investing activities primarily consisted of purchases of property, plant, and equipment of $43.3 million, which increased $12.2 million in Q1 FY24, compared with Q1 FY23.

    Financing Activities: Net cash used in financing activities decreased by $6.8 million in Q1 FY24, compared with Q1 FY23, primarily due to decreased debt repayments of $8.0 million.

The increase in our cash balance from Q1 FY23 was favorably impacted by the effects of exchange rate changes in the amount of $13.0 million in Q1 FY24, which was less than the $27.5 million favorable impact of exchange rate changes had on our cash balance in Q1 FY23.

Non-GAAP Financial Measures

Non-GAAP Non-operating (loss) income, Non-GAAP Income tax provision, Non-GAAP Noncontrolling interests, Non-GAAP Net Income attributable to Photronics, Inc. shareholders and non-GAAP earnings per share, Free Cash Flow, and Net Cash are "non-GAAP financial measures" as such term is defined by the Securities and Exchange Commission and may differ from similarly named non-GAAP financial measures used by other companies. The financial tables below reconcile Photronics, Inc. financial results under GAAP to non-GAAP financial information. We believe these non-GAAP financial measures that exclude certain items are useful for analysts and investors to evaluate our future on-going performance because they enable a more meaningful comparison of our projected performance with our historical results. These non-GAAP metrics are not intended to represent funds available for our discretionary use and are not intended to represent, or be used as a substitute for, net income attributable to Photronics, Inc. shareholders, diluted earnings per share, cash and cash equivalents, or cash flows from operations, as measured under GAAP. The items excluded from these non-GAAP metrics but included in the calculation of their closest GAAP equivalent, are significant components of the condensed consolidated statements of income, condensed consolidated balance sheets and statement of cash flows and must be considered in performing a comprehensive assessment of overall financial performance.
 
The following table reconciles GAAP to Non-GAAP Income at the balance sheet dates. The columns may not foot due to rounding.

   
Three Months ended
 
   
January 28,
   
October 31,
   
January 29,
 
   
2024
   
2023
   
2023
 
Reconciliation of GAAP to Non-GAAP Non-operating (loss) Income:
                 
                   
GAAP Non-operating (loss) income, net
 
$
(3,747
)
 
$
18,660
   
$
(14,425
)
FX (gain) loss
   
8,909
     
(13,234
)
   
16,944
 
Non-GAAP Non-operating (loss) income, net
 
$
5,162
   
$
5,426
   
$
2,519
 
                         
Reconciliation of GAAP to Non-GAAP Income tax provision:
                       
                         
GAAP Income tax provision
 
$
14,660
   
$
20,288
   
$
12,582
 
Estimated tax effects of FX (gain) loss
   
(2,244
)
   
3,437
     
(4,506
)
Non-GAAP Income tax provision
 
$
16,904
   
$
16,851
   
$
17,088
 
                         
Reconciliation of GAAP to Non-GAAP Noncontrolling interests:
                       
                         
GAAP Noncontrolling interests
 
$
12,902
   
$
18,545
   
$
14,964
 
Estimated noncontrolling interest effects of above
   
(2,939
)
   
2,431
     
(2,060
)
Non-GAAP Noncontrolling interests
 
$
15,841
   
$
16,114
   
$
17,024
 
                         
Reconciliation of GAAP to Non-GAAP Net Income:
                       
                         
GAAP Net Income
 
$
26,180
   
$
44,611
   
$
13,986
 
FX (gain) loss
   
8,909
     
(13,234
)
   
16,944
 
Estimated tax effects of above
   
(2,244
)
   
3,437
     
(4,506
)
Estimated noncontrolling interest effects of above
   
(2,939
)
   
2,431
     
(2,060
)
Non-GAAP Net Income
 
$
29,906
   
$
37,245
   
$
24,364
 
                         
Weighted-average number of common shares outstanding – Diluted
   
62,283
     
62,067
     
61,470
 
                         
Reconciliation of GAAP to Non-GAAP EPS:
                       
                         
GAAP diluted earnings per share
 
$
0.42
   
$
0.72
   
$
0.23
 
Effects of the above adjustments
 
$
0.06
   
$
(0.12
)
 
$
0.17
 
Non-GAAP diluted earnings per share
 
$
0.48
   
$
0.60
   
$
0.40
 

The following tables reconcile Net cash provided by operating activities to Free Cash Flow for Q1 FY24 and Q1 FY23. The columns may not foot due to rounding. Prior year amounts in the non-GAAP disclosure below have been recast to eliminate government incentives to conform to current year presentation.
 
   
Q1 FY24
   
Q1 FY23
 
Free Cash Flow
           
Net cash provided by operating activities
 
$
41.5
   
$
27.7
 
Purchases of property, plant, and equipment
   
(43.3
)
   
(31.1
)
Free cash flow
 
$
(1.8
)
 
$
(3.4
)

The following table reconciles Cash and cash equivalents to Net Cash at the balance sheet dates. The increase in Net Cash was primarily driven by proceeds from maturities of available-for-sale debt securities, decreased debt repayments and increase in Net cash provided by operating activities, as discussed above. The columns may not foot due to rounding. Prior year amounts in the non-GAAP disclosure below have been recast to eliminate government incentives to conform to current year presentation.

   
As of
 
   
January 28,
   
October 31,
   
January 29,
 
   
2024
   
2023
   
2023
 
Net Cash
                 
Cash and cash equivalents
 
$
508.5
   
$
499.3
   
$
334.8
 
Current portion of Long-term debt
   
(20.8
)
   
(6.6
)
   
(6.6
)
Long-term debt
   
(2.7
)
   
(18.0
)
   
(27.3
)
Net cash
 
$
485.0
   
$
474.7
   
$
300.9
 

Business Outlook

Our current business outlook and guidance was provided in the Photronics Q1 FY24 earnings release, earnings presentation, and financial results conference call, but is not incorporated herein. These can be accessed in the investor section of our website - www.photronics.com.

    Our future results of operations and the other forward-looking statements contained in this filing and in the Photronics Q1 FY24 earnings release, and the related financial results conference call and earnings presentation involve a number of risks and uncertainties, some of which were discussed in Part I, Item 1A of our 2023 Form 10-K. A number of other unforeseeable factors could cause actual results to differ materially from our expectations.

Critical Accounting Estimates

Please refer to Part II, Item 7 of our 2023 Form 10-K for discussion of our critical accounting estimates. There have been no changes to our critical accounting estimates since the filing of our Form 10-K for the year ended October 31, 2023.

Item 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Foreign Currency Exchange Rate Risk

We conduct business in several major international currencies throughout our worldwide operations, and our financial performance may be affected by fluctuations in the exchange rates of these currencies. Changes in exchange rates can positively or negatively affect our reported revenue, operating income, assets, liabilities, and equity. The functional currencies of our Asian subsidiaries are the South Korean won, the New Taiwan dollar, the RMB, and the Singapore dollar. The functional currencies of our European subsidiaries are the British pound and the euro. In addition, we engage in transactions in, and have exposures to, the Japanese yen.

We attempt to minimize our risk of foreign currency transaction losses by producing products in the same country in which the products are sold (thereby generating revenues and incurring expenses in the same currency), and by managing our working capital. However, in some instances, we sell products in a currency other than the functional currency of the country where it was produced, or purchase products in a currency that differs from the functional currency of the purchasing entity. We may also enter into derivative contracts to mitigate our exposure to foreign currency fluctuations when we have a significant purchase obligation, or a significant receivable denominated in a currency that differs from the functional currency of the transacting subsidiary. We do not enter into derivatives for speculative purposes. There can be no assurance that this approach will protect us from the need to recognize significant foreign currency transaction gains and losses, especially in the event of a significant adverse movement in the value of any foreign currency in which we conduct business against any of our functional currencies, including the U.S. dollar.

Our primary net foreign currency exposures as of January 28, 2024, included the South Korean won, the Japanese yen, the New Taiwan dollar, the RMB, the Singapore dollar, the British pound sterling, and the euro. As of that date, a 10% adverse movement in the value of currencies different from the functional currencies of our subsidiaries would have resulted in a net unrealized pre-tax loss of $54.8 million, which represents an increase of $2.7 million from our exposure at October 31, 2023. Our most significant exposures at January 28, 2024, were exposures of the South Korean won, the RMB, and the New Taiwan Dollar to the U.S. dollar, which were, respectively, $13.8 million, $9.7 million, and $28.4 million at that date. We do not believe that a 10% change in the exchange rates of non-US dollar currencies, other than the aforementioned currencies and the Japanese yen, would have had a material effect on our January 28, 2024, condensed consolidated financial statements.

Interest Rate Risk

A 10% adverse movement in the interest rates on our variable rate borrowings would not have had a material effect on our January 28, 2024, condensed consolidated financial statements.
 
Item 4.
CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We have established, and currently maintain, disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act, designed to provide reasonable assurance that information required to be disclosed in reports filed under the Exchange Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to management, including our chief executive officer and interim chief financial officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our management, under the supervision and with the participation of our chief executive officer and interim chief financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation, our chief executive officer and interim chief financial officer concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of the end of the period covered by this report.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the first fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II.
OTHER INFORMATION

Item 1.
LEGAL PROCEEDINGS

Please refer to Note 12 within Item 1 of this report for information on legal proceedings involving the Company.

Item 1A.
RISK FACTORS

There have been no material changes to our risk factors as set forth in “Item 1A. Risk Factors” in our 2023 Form 10-K.

Item 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities

In September 2020, the Company’s board of directors authorized the repurchase of up to $100 million of its common stock, pursuant to a repurchase plan under Rule 10b5-1 of the Securities Act. The share repurchase program commenced on September 16, 2020, and all shares repurchased under this program were retired. The following table provides information relating to the Company’s repurchase of common stock for the first quarter of 2024. This table excludes shares repurchased to settle employee tax withholding related to the vesting of stock awards.

   
Total Number of
Shares
Purchased
   
Average
Price
Paid
Per share
   
Total Number of
shares Purchased
as Part of Publicly
Announced
Program
   
Dollar Value of
Shares That May
Yet Be Purchased
(in millions)
 
                         
                         
                         
November 1, 2023 – November 26, 2023
   
-
     
-
     
-
   
$
31.7
 
November 27, 2023 – December 24, 2023
   
-
     
-
     
-
   
$
31.7
 
December 25, 2023 – January 28, 2024
   
-
     
-
     
-
   
$
31.7
 
Total
                   
-
         
 
Certain lease arrangements include limitations on the amounts of dividends we may pay. Please refer to Note 7 of the condensed consolidated financial statements for information on these limitations.

Item 3.
DEFAULTS UPON SENIOR SECURITIES

Not applicable

Item 4.
MINE SAFETY DISCLOSURES

Not applicable

Item 5.
OTHER INFORMATION

Securities Trading Plans of Directors and Executive Officers

The following officer, as defined in Rule 16a-1(f) of the Exchange Act, adopted a “Rule 10b5-1 trading arrangement,” as defined in Item 408 of Regulation S-K, as follows:

On January 11, 2024, Lucien Bouchard, our Vice President of Global Sales and Global Sales Engineering, adopted a Rule 10b5-1 trading arrangement, (the “Plan”) providing for the sale of an aggregate of up to 9,000 shares of our common stock granted to Mr. Bouchard under our compensation program. The Plan is intended to satisfy the affirmative defense in Rule 10b5-1(c). The first date that sales of any shares are permitted to be sold under the Plan was February 12, 2024. All shares under the Plan have been traded.
No other officers or directors, as defined in Rule 16a-1(f), adopted and/or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Item 408 of Regulation S-K, during the last fiscal quarter.

Item 6.
EXHIBITS

   
Incorporated by Reference
     
Exhibit
Number
 
Description
Form
Exhibit
Filing Date
Filed or
Furnished
Herewith
           
Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
X
           
Certification of Interim Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
     
X
           
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
X
           
Certification of Interim Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
     
X
           
101.INS
Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
     
 
 
X
           
101.SCH
Inline XBRL Taxonomy Extension Schema Document
     
X
           
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document
     
X
           
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document
     
X
           
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document
     
X
           
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document
     
X
           
104
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
     
 
X

SIGNATURES

   Pursuant to the requirements of the Exchange Act, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Photronics, Inc.


(Registrant)

 
 
By:
/s/ ERIC RIVERA


ERIC RIVERA


Vice President,
Interim Chief Financial Officer,


Corporate Controller


(Principal Financial Officer
/Principal Accounting Officer)




Date:  March 7, 2024



36


EXHIBIT 31.1

I, Frank Lee, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of Photronics, Inc.

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c)
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d)
disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):


a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and


b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ FRANK LEE
 
Frank Lee
 
Chief Executive Officer
 
March 7, 2024
 




EXHIBIT 31.2

I, Eric Rivera, certify that:

1.
I have reviewed this quarterly report on Form 10-Q of Photronics, Inc.

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


c)
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


d)
disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):


a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and


b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
/s/ ERIC RIVERA
 
Eric Rivera
 
Interim Chief Financial Officer
 
March 7, 2024
 

 


EXHIBIT 32.1

Section 1350 Certification of the Chief Executive Officer

I, Frank Lee, Chief Executive Officer of Photronics, Inc. (the “Company”), certify, to my knowledge, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

(1)
The Quarterly Report on Form 10-Q of the Company for the quarter ended January 28, 2024 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

The foregoing certification is being furnished pursuant to 18 U.S.C. § 1350 and will not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.
 
/s/ FRANK LEE
 
Frank Lee
 
Chief Executive Officer
 
March 7, 2024
 




EXHIBIT 32.2

Section 1350 Certification of the Chief Financial Officer

I, Eric Rivera, Interim Chief Financial Officer of Photronics, Inc. (the “Company”), certify, to my knowledge, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:

(1)
The Quarterly Report on Form 10-Q of the Company for the quarter ended January 28, 2024 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

The foregoing certification is being furnished pursuant to 18 U.S.C. § 1350 and will not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.

/s/ ERIC RIVERA
 
Eric Rivera
 
Interim Chief Financial Officer
 
March 7, 2024
 

 
v3.24.0.1
Document and Entity Information - shares
3 Months Ended
Jan. 28, 2024
Feb. 29, 2024
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Period End Date Jan. 28, 2024  
Current Fiscal Year End Date --10-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Document Transition Report false  
Entity File Number 000-15451  
Entity Registrant Name PHOTRONICS, INC.  
Entity Central Index Key 0000810136  
Entity Incorporation, State or Country Code CT  
Entity Tax Identification Number 06-0854886  
Entity Address, Address Line One 15 Secor Road  
Entity Address, City or Town Brookfield  
Entity Address, State or Province CT  
Entity Address, Postal Zip Code 06804  
City Area Code 203  
Local Phone Number 775-9000  
Title of 12(b) Security COMMON  
Trading Symbol PLAB  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   63,353,714
v3.24.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jan. 28, 2024
Oct. 31, 2023
Current assets:    
Cash and cash equivalents $ 508,518 $ 499,292
Short-term investments 12,996 12,915
Accounts receivable, net of allowance of $1,090 in 2024 and $1,099 in 2023 203,607 194,927
Inventories 50,680 49,963
Other current assets 31,876 28,353
Total current assets 807,677 785,450
Property, plant and equipment, net 742,671 709,244
Deferred income taxes 22,223 21,297
Other assets 10,265 10,230
Total assets 1,582,836 1,526,221
Current liabilities:    
Current portion of long-term debt 20,771 6,621
Accounts payable 86,925 84,024
Accrued liabilities 77,593 94,578
Total current liabilities 185,289 185,223
Long-term debt 2,655 17,998
Other liabilities 47,838 47,391
Total liabilities 235,782 250,612
Commitments and contingencies
Equity:    
Preferred stock, $0.01 par value, 2,000 shares authorized, none issued and outstanding 0 0
Common stock, $0.01 par value, 150,000 shares authorized, 61,746 shares issued and outstanding at January 28, 2024, and 61,310 shares issued and outstanding at October 31, 2023 617 613
Additional paid-in capital 502,903 502,010
Retained earnings 587,299 561,119
Accumulated other comprehensive loss (67,863) (88,734)
Total Photronics, Inc. shareholders' equity 1,022,956 975,008
Noncontrolling interests 324,098 300,601
Total equity 1,347,054 1,275,609
Total liabilities and equity $ 1,582,836 $ 1,526,221
v3.24.0.1
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
shares in Thousands, $ in Thousands
Jan. 28, 2024
Oct. 31, 2023
Current assets:    
Accounts receivable, allowance $ 1,090 $ 1,099
Equity:    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 2,000 2,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 150,000 150,000
Common stock, shares issued (in shares) 61,746 61,310
Common stock, shares outstanding (in shares) 61,746 61,310
v3.24.0.1
Condensed Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Jan. 28, 2024
Jan. 29, 2023
Condensed Consolidated Statements of Income [Abstract]    
Revenue [1] $ 216,334 $ 211,090
Cost of goods sold 137,079 135,013
Gross profit 79,255 76,077
Operating expenses:    
Selling, general and administrative 18,321 16,818
Research and development 3,445 3,302
Total operating expenses 21,766 20,120
Operating income 57,489 55,957
Other income (expense):    
Foreign currency transactions impact, net (8,908) (16,944)
Interest income and other income, net 5,251 2,584
Interest expense (90) (65)
Income before income tax provision 53,742 41,532
Income tax provision 14,660 12,582
Net income 39,082 28,950
Net income attributable to noncontrolling interests 12,902 14,964
Net income attributable to Photronics, Inc. shareholders $ 26,180 $ 13,986
Earnings per share:    
Basic (in dollars per share) $ 0.43 $ 0.23
Diluted (in dollars per share) $ 0.42 $ 0.23
Weighted-average number of common shares outstanding:    
Basic (in shares) 61,455 60,894
Diluted (in shares) 62,283 61,470
[1] This table disaggregates revenue by the location in which it was earned.
v3.24.0.1
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
3 Months Ended
Jan. 28, 2024
Jan. 29, 2023
Condensed Consolidated Statements of Comprehensive Income [Abstract]    
Net income $ 39,082 $ 28,950
Other comprehensive (loss) income, net of tax of $0:    
Foreign currency translation adjustments 31,493 90,519
Other (27) (54)
Net other comprehensive (loss) income 31,466 90,465
Comprehensive income 70,548 119,415
Less: comprehensive income attributable to noncontrolling interests 23,497 31,393
Comprehensive income attributable to Photronics, Inc. shareholders $ 47,051 $ 88,022
v3.24.0.1
Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended
Jan. 28, 2024
Jan. 29, 2023
Condensed Consolidated Statements of Comprehensive Income [Abstract]    
Other comprehensive (loss) income, tax $ 0 $ 0
v3.24.0.1
Condensed Consolidated Statements of Equity - USD ($)
shares in Thousands, $ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Non-controlling Interests [Member]
Total
Balance at Oct. 31, 2022 $ 608 $ 493,741 $ 435,634 $ (98,456) $ 230,562 $ 1,062,089
Balance (in shares) at Oct. 31, 2022 60,791          
Net income $ 0 0 13,986 0 14,964 28,950
Other comprehensive income 0 0 0 74,036 16,429 90,465
Shares issued under equity plans $ 3 (608) 0 0 0 (605)
Shares issued under equity plans (in shares) 311          
Share-based compensation expense $ 0 1,821 0 0 0 1,821
Balance at Jan. 29, 2023 $ 611 494,954 449,620 (24,420) 261,955 1,182,720
Balance (in shares) at Jan. 29, 2023 61,102          
Balance at Oct. 31, 2023 $ 613 502,010 561,119 (88,734) 300,601 1,275,609
Balance (in shares) at Oct. 31, 2023 61,310          
Net income $ 0 0 26,180 0 12,902 39,082
Other comprehensive income 0 0 0 20,871 10,595 31,466
Shares issued under equity plans $ 4 (1,680) 0 0 0 (1,676)
Shares issued under equity plans (in shares) 436          
Share-based compensation expense $ 0 2,573 0 0 0 2,573
Balance at Jan. 28, 2024 $ 617 $ 502,903 $ 587,299 $ (67,863) $ 324,098 $ 1,347,054
Balance (in shares) at Jan. 28, 2024 61,746          
v3.24.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Jan. 28, 2024
Jan. 29, 2023
Cash flows from operating activities:    
Net income $ 39,082 $ 28,950
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 20,702 19,105
Share-based compensation 2,573 1,821
Changes in assets and liabilities:    
Accounts receivable (2,906) (7,565)
Inventories 409 1,705
Other current assets (2,844) (13,060)
Accounts payable, accrued liabilities, and other (15,508) (3,276)
Net cash provided by operating activities 41,508 27,680
Cash flows from investing activities:    
Purchases of property, plant and equipment (43,314) (31,097)
Purchases of available-for-sale debt securities (2,436) 0
Proceeds from maturities of available-for-sale debt securities 2,500 0
Government incentives 1,091 1,014
Other (56) (87)
Net cash used in investing activities (42,215) (30,170)
Cash flows from financing activities:    
Repayments of debt (1,194) (9,218)
Proceeds from share-based arrangements 936 672
Net settlements of restricted stock awards (2,613) (1,168)
Net cash used in financing activities (2,871) (9,714)
Effects of exchange rate changes on cash, cash equivalents, and restricted cash 13,026 27,499
Net increase (decrease) in cash, cash equivalents, and restricted cash 9,448 15,295
Cash, cash equivalents, and restricted cash at beginning of period 501,867 322,409
Cash, cash equivalents, and restricted cash at end of period 511,315 337,704
Less: Ending restricted cash 2,797 2,912
Cash and cash equivalents at end of period 508,518 334,792
Supplemental disclosure of non-cash information:    
Accruals for property, plant and equipment purchased during the period $ 1,628 $ 12,031
v3.24.0.1
BASIS OF FINANCIAL STATEMENT PRESENTATION
3 Months Ended
Jan. 28, 2024
BASIS OF FINANCIAL STATEMENT PRESENTATION [Abstract]  
BASIS OF FINANCIAL STATEMENT PRESENTATION
NOTE 1 - BASIS OF FINANCIAL STATEMENT PRESENTATION


Photronics, Inc. (“Photronics”, “the Company”, “we”, “our”, or “us”) is  one of the world’s leading manufacturers of photomasks, which are high-precision photographic quartz or glass plates containing microscopic images of electronic circuits. Photomasks are a key element in the manufacture of ICs and FPDs and are used as masters to transfer circuit patterns onto semiconductor wafers and FPD substrates during the fabrication of ICs, a variety of FPDs and, to a lesser extent, other types of electrical and optical components. We operate eleven manufacturing facilities, which are located in Taiwan (3), Korea, China (2), the United States (3), and Europe (2).


The accompanying unaudited condensed consolidated financial statements (“the financial statements”) have been prepared in accordance with U.S. GAAP for interim financial information, and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for annual financial statements. In the opinion of management, adjustments, all of which are of a normal recurring nature, considered necessary for a fair presentation have been included. The financial statements include the accounts of Photronics, its wholly owned subsidiaries, and the majority-owned subsidiaries, which it controls. All intercompany balances and transactions have been eliminated in consolidation. These financial statements should be read in conjunction with the consolidated financial statements and accompanying notes included in our Form 10-K for the fiscal year ended October 31, 2023, where we discuss and provide additional information about our accounting policies and the methods and assumptions used in our estimates.


The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect amounts reported in them. Our estimates are based on historical experience and on various assumptions that we believe to be reasonable under the facts and circumstances at the time they are made. Subsequent actual results may differ from such estimates. We review these estimates periodically and reflect any effects of revisions in the period in which they are determined.



Our business is typically impacted during the first quarter of our fiscal year by the North American, European, and Asian holiday periods, as some customers reduce their development and buying activities during this period. Operating results for the interim periods are not necessarily indicative of the results that may be expected for the fiscal year ending October 31, 2024.
v3.24.0.1
ACCOUNT RECEIVABLES
3 Months Ended
Jan. 28, 2024
ACCOUNT RECEIVABLES [Abstract]  
ACCOUNT RECEIVABLES
NOTE 2 - ACCOUNT RECEIVABLES
 
The components of Accounts Receivable at the balance sheet dates are presented below.
 
 
 
January 28,
   
October 31,
 
 
 
2024
   
2023
 
Accounts Receivable
 
$
176,146
   
$
171,433
 
Unbilled Receivable
   
28,551
     
24,593
 
Allowance for Credit Losses
   
(1,090
)
   
(1,099
)
 
 
$
203,607
   
$
194,927
 
v3.24.0.1
SHORT-TERM INVESTMENTS
3 Months Ended
Jan. 28, 2024
SHORT-TERM INVESTMENTS [Abstract]  
SHORT-TERM INVESTMENTS

NOTE 3 - SHORT-TERM INVESTMENTS



Short-term investments consist of U.S. government securities and are classified as available-for-sale. We classify available-for-sale securities on our consolidated balance sheet as follows:


-
Maturing within three months or less from the date of purchase
Cash and cash equivalents
-
Maturing, as of the date of purchase, more than three months, but
with remaining maturities of less than one year, from the balance sheet date
Short-term investments
-
Maturing one year or more from the balance sheet date
Long-term marketable investments


       As of January 28, 2024, all of our available-for-sale securities had, at their dates of purchase, remaining maturities of more than three months, but less than one year, and have been classified as Short-term investments.



Available-for-sale debt investments are reported at fair value, with unrealized gains or losses (net of tax) reported in Accumulated other comprehensive income. The fair values of our available-for-sale securities are Level 1 measurements, based on quoted prices from active markets for identical assets. In the event of a sale of an available-for-sale debt investment, we would determine the cost of the investment sold at the specific individual security level and would include any gain or loss in Interest income and other income, net, where we also report periodic interest earned and the amortization (accretion) of discounts (premiums) related to these investments. The table below provides information on our available-for-sale debt securities.


   
January 28, 2024
   
October 31, 2023
 
   
Amortized
Cost
   
Unrealized
Gains
   
Unrealized
Losses
   
Carrying
Value
   
Amortized
Cost
   
Unrealized
Gains
   
Unrealized
Losses
   
Carrying
Value
 
Government securities
 
$
12,994
   
$
3
   
$
(1
)
 
$
12,996
   
$
12,913
   
$
4
   
$
(2
)
 
$
12,915
 
v3.24.0.1
INVENTORIES
3 Months Ended
Jan. 28, 2024
INVENTORIES [Abstract]  
INVENTORIES
NOTE 4 - INVENTORIES


Inventories are stated at the lower of cost, determined under the first-in, first-out (“FIFO”) method, or net realizable value. Presented below are the components of Inventories at the balance sheet dates.

 
January 28,
2024
   
October 31,
2023
 
Raw materials
 
$
49,669
   
$
48,948
 
Work in process
   
1,000
     
1,010
 
Finished goods
   
11
     
5
 
   
$
50,680
   
$
49,963
 
v3.24.0.1
PROPERTY, PLANT, AND EQUIPMENT, NET
3 Months Ended
Jan. 28, 2024
PROPERTY, PLANT, AND EQUIPMENT, NET [Abstract]  
PROPERTY, PLANT, AND EQUIPMENT, NET
NOTE 5 - PROPERTY, PLANT, AND EQUIPMENT, NET


Presented below are the components of Property, plant, and equipment, net at the balance sheet dates.


 
January 28,
2024
   
October 31,
2023
 
Land
 
$
11,537
   
$
11,378
 
Buildings and improvements
   
189,152
     
185,850
 
Machinery and equipment
   
1,968,318
     
1,922,041
 
Leasehold improvements
   
19,572
     
18,894
 
Furniture, fixtures, and office equipment
   
16,985
     
15,856
 
Construction in progress
   
84,356
     
55,434
 
     
2,289,920
     
2,209,453
 
Accumulated depreciation and amortization
   
(1,547,249
)
   
(1,500,209
)
   
$
742,671
   
$
709,244
 


Information on ROU assets resulting from finance leases, at the balance sheet dates, is presented below.

 
 
January 28,
2024
   
October 31,
2023
 
Machinery and equipment
 
$
42,817
   
$
42,820
 
Accumulated amortization
   
(8,351
)
   
(7,655
)
 
 
$
34,466
   
$
35,165
 


The following table presents depreciation expense (including the amortization of ROU assets) related to property, plant, and equipment incurred during the reporting periods.

 
Three Months Ended
 
 
January 28,
2024
 
January 29,
2023
 
Depreciation Expense   $ 20,605     $ 19,028  
v3.24.0.1
PDMCX JOINT VENTURE
3 Months Ended
Jan. 28, 2024
PDMCX JOINT VENTURE [Abstract]  
PDMCX JOINT VENTURE
NOTE 6 - PDMCX JOINT VENTURE


In January 2018, Photronics, Inc., through its wholly owned Singapore subsidiary (hereinafter, within this Note “we”, “Photronics”, “us”, or “our”), and DNP, through its wholly owned subsidiary “DNP Asia Pacific PTE, Ltd.”, entered into a joint venture under which DNP obtained a 49.99% interest in our IC business in Xiamen, China. The joint venture, which we refer to as “PDMCX”, was established to develop and manufacture photomasks for semiconductors. We entered into this joint venture to enable us to compete more effectively for the merchant photomask business in China, and to benefit from the additional resources and investment that DNP provides to enable us to offer advanced-process technology to our customers.



In 2020, in combination with local financing obtained by PDMCX, Photronics and DNP fulfilled their investment obligations under the PDMCX operating agreement (the Agreement”). As discussed in Note 7, liens were granted to the local financing entity on property, plant, and equipment and were paid off during fiscal year 2023 and there was no remaining debt at October 31, 2023.


Under the Agreement, DNP is afforded, under certain circumstances, the right to put its interest in PDMCX to Photronics. These circumstances include disputes regarding the strategic direction of PDMCX that may arise after the initial two-year term of the Agreement and cannot be resolved between the two parties. As of the date of issuance of these financial statements, DNP had not indicated its intention to exercise this right. In addition, both Photronics and DNP have the option to purchase, or put, their interest from, or to, the other party, should their ownership interest fall below 20.0% for a period of more than six consecutive months. Under all such circumstances, the sales of ownership interests would be at the exiting party’s ownership percentage of the joint venture’s net book value, with closing to take place within three business days of obtaining required approvals and clearance.


The following table presents net income we recorded from the operations of PDMCX during the reporting periods.

   
Three Months Ended
 

 
January 28,
2024
   
January 29,
2023
 
Net income from PDMCX
 
$
6,463
   
$
5,918
 


As required by the guidance in Topic 810 - “Consolidation” of the Accounting Standards Codification (“ASC”), we evaluated our involvement in PDMCX for the purpose of determining whether we should consolidate its results in our financial statements. The initial step of our evaluation was to determine whether PDMCX was a variable interest entity (“VIE”). Due to its lack of sufficient equity at risk to finance its activities without additional subordinated financial support, we determined that it was a VIE. Having made this determination, we then assessed whether we were the primary beneficiary of the VIE and concluded that we were the primary beneficiary during the current and prior year reporting periods; thus, as required, the PDMCX financial results have been consolidated with Photronics. Our conclusion was based on the facts that we held a controlling financial interest in PDMCX (which resulted from our having the power to direct the activities that most significantly impacted its economic performance) and had the obligation to absorb losses and the right to receive benefits that could potentially be significant to PDMCX. Our conclusions that we had the power to direct the activities that most significantly affected the economic performance of PDMCX during the current and prior year reporting periods were based on our right to appoint the majority of its board of directors, which has, among others, the powers to manage the business (through its rights to appoint and evaluate PDMCX’s management), incur indebtedness, enter into agreements and commitments, and acquire and dispose of PDMCX’s assets. In addition, as a result of the 50.01% variable interest we held during the current and prior year periods, we had the obligation to absorb losses, and the right to receive benefits, that could potentially be significant to PDMCX.


The following table presents the carrying amounts of PDMCX assets and liabilities included in our condensed consolidated balance sheets. General creditors of PDMCX do not have recourse to the assets of Photronics (other than the net assets of PDMCX); therefore, our maximum exposure to loss from PDMCX is our interest in the carrying amount of the net assets of the joint venture.


 
January 28,
2024
   
October 31,
2023
 
Classification
 
Carrying
Amount
   
Photronics
Interest
   
Carrying
Amount
   
Photronics
Interest
 
Current assets
 
$
143,250
   
$
71,639
   
$
135,960
   
$
67,994
 
Noncurrent assets
   
150,077
     
75,054
     
136,334
     
68,181
 
Total assets
   
293,327
     
146,693
     
272,294
     
136,175
 
                                 
Current liabilities
   
36,661
     
18,334
     
36,305
     
18,156
 
Noncurrent liabilities
   
1,929
     
965
     
1,873
     
937
 
Total liabilities
   
38,590
     
19,299
     
38,178
     
19,093
 
                                 
Net assets
 
$
254,737
   
$
127,394
   
$
234,116
   
$
117,082
 
v3.24.0.1
DEBT
3 Months Ended
Jan. 28, 2024
DEBT [Abstract]  
DEBT
NOTE 7 - DEBT


As of January 28, 2024, the Current portion of long-term debt and the Long-term debt balances were comprised of finance leases as described below:

As of January 28, 2024
 
Finance
Leases
 
Principal due:
     
Next 12 months
 
$
20,771
 
Months 13 – 24
 
$
2,632
 
Months 25 – 36
   
12
 
Months 37 – 48
   
11
 
Months 49 – 60
    -  
Long-term debt
   
2,655
 
Total debt
  $ 23,426  
 
       
Interest rate at balance sheet date
    N/A
 
Basis spread on interest rates
   
N/A
 
Interest rate reset
   
N/A
 
Maturity date
    N/A
 
Periodic payment amount     Varies as Lease mature  
Periodic payment frequency
 
Monthly
 
Loan collateral (carrying amount)
 
$
34,466
(1) 

 
(1)
Represents the carrying amount at the balance sheet date of the related ROU assets, in which the lessors have secured interests.


The table below provides information on our long-term debt as of October 31, 2023.

As of October 31, 2023
 
Finance
Leases
 
Principal due:
      
Next 12 months
  $ 6,621  
Months 13 – 24
  $ 17,972  
Months 25 – 36
    12  
Months 37 – 48
    13  
Months 49 – 60
     1
   
Long-term debt
 
17,998  
Total debt
  $ 24,619
 
 
          
Interest rate at balance sheet date
    N/A  
Basis spread on interest rates
    N/A  
Interest rate reset     N/A
 
Maturity date
    N/A
 
Periodic payment amount     Varies as Lease mature  
Periodic payment frequency     Monthly  
Loan collateral (carrying amount)
  $ 35,165 (1)

 
(1)
Represents the carrying amount at the balance sheet date of the related ROU assets, in which the lessors have secured interests.

Finance Leases


In February 2021, we entered into a five-year $7.2 million finance lease for a high-end inspection tool. Monthly payments on the lease, which commenced in February 2021, are $0.1 million per month. Upon the payment of the fiftieth monthly payment and prior to payment of the fifty-first monthly payment, we may exercise an early buyout option to purchase the tool for $2.4 million. If we do not exercise the early buyout option, then at the end of the five-year lease term, the lease shall continue to renew on a month-to-month basis at the same rental terms; at our option, after the original term or any renewal periods, we may return the tool, elect to extend the lease, or purchase the tool at its fair market value. Since we are reasonably certain that we will exercise the early buyout option, our lease liability reflects such exercise and we have classified the lease as a finance lease. The interest rate implicit in the lease is 1.08%.



In December 2020, we entered into a five-year $35.5 million finance lease for a high-end lithography tool. Monthly payments on the lease, which commenced in January 2021, increased from $0.04 million during the first three months to $0.6 million for the following nine months, followed by forty-eight monthly payments of $0.5 million. As of the due date of the forty-eighth monthly payment, we may exercise an early buyout option to purchase the tool for $14.1 million. If we do not exercise the early buyout option, then at the end of the five-year lease term, at our option, we may return the tool, elect to extend the lease term for a period and a lease payment to be agreed with lessor at the time, or purchase the tool for its then-fair market value, as determined by the lessor. Since we are reasonably certain that we will exercise the early buyout option, our lease liability reflects such exercise and we have classified the lease as a finance lease. The interest rate implicit in the lease is 1.58%. The lease agreement incorporates the covenants included in our Credit Agreement, as defined below (expired in September 2023), which are detailed below, and includes a cross-default provision for any agreement or instrument with an outstanding, committed balance greater than $5.0 million in which we are the indebted party.


Corporate Credit Agreement


In September 2018, we entered into a five-year amended and restated credit agreement (the “Credit Agreement”), which had a $50 million borrowing limit, with an expansion capacity to $100 million. The Credit Agreement was secured by substantially all of our assets located in the United States and common stock we own in certain subsidiaries. The Credit Agreement was subject to covenants around minimum interest coverage ratio, total leverage ratio, and minimum unrestricted cash balance (all of which we were in compliance with at the termination of the agreement in September 2023), and limited the amount of cash dividends, distributions, and redemptions we could pay on our common stock to an aggregate annual amount of $50 million. The Credit Agreement expired, and was not renewed as of October 31, 2023.  There were no outstanding borrowings against the Credit Agreement at its expiration.


Xiamen Working Capital Loans


In November 2018, PDMCX obtained approval for revolving, unsecured credit of the equivalent of $25.0 million, pursuant to which PDMCX may enter into separate loan agreements with varying terms to maturity. This facility is subject to annual reviews and extensions, with the most recent extension set to expire in July 2024. In December 2022, we repaid our entire outstanding balance of RMB 25.6 million ($3.6 million). As of January 28, 2024, PDMCX had no amount outstanding against the approval. The interest rates are variable, based on the RMB Loan Prime Rate of the National Interbank Funding Center. Interest incurred on the loans related to the amount borrowed was eligible for reimbursement through incentives provided by the Xiamen Torch Hi-Tech Industrial Development Zone, which provided for such reimbursements up to a prescribed limit and duration.
v3.24.0.1
REVENUE
3 Months Ended
Jan. 28, 2024
REVENUE [Abstract]  
REVENUE
NOTE 8 - REVENUE


We recognize revenue when, or as, control of a good or service transfers to a customer, in an amount that reflects the consideration to which we expect to be entitled in exchange for transferring those goods or services. We account for an arrangement as a revenue contract when each party has approved and is committed to perform under the contract, the rights of the contracting parties regarding the goods or services to be transferred and the payment terms are identifiable, the arrangement has commercial substance, and collection of consideration is probable. Substantially all of our revenue comes from the sales of photomasks. We typically contract with our customers to sell sets of photomasks, which are comprised of multiple layers, the predominance of which we invoice as they ship to customers. As the photomasks are manufactured to customer specifications, they have no alternative use to us and, as our contracts generally provide us with the right to payment for work completed to date, we recognize revenue as we perform, or “over time”, on most of our contracts. We measure our performance to date using an input method, which is based on our estimated costs to complete the various manufacturing phases of a photomask. At the end of a reporting period, there are a number of uncompleted revenue contracts on which we have performed; for any such contracts under which we are entitled to be compensated for our costs incurred plus a reasonable profit, we recognize revenue and a corresponding contract asset for such performance. We account for shipping and handling activities that we perform after a customer obtains control of a good as being activities to fulfill our promise to transfer the good to the customer, rather than as promised services, or performance obligations, under the contract. We report our revenue net of any sales or similar taxes we collect on behalf of government entities.


As stated above, photomasks are manufactured to customer specifications in accordance with their proprietary designs; thus, they are individually unique. Due to their uniqueness and other factors, their transaction prices are individually established through negotiations with customers; consequently, our photomasks do not have standard or “list” prices. The transaction prices of the vast majority of our revenue contracts include only fixed amounts of consideration. In certain instances, such as when we offer a customer an early payment discount, an estimate of variable consideration would be included in the transaction price, but only to the extent that a significant reversal of revenue would not occur when the uncertainty related to the variability was resolved.

Contract Assets, Contract Liabilities, and Accounts Receivable

We recognize a contract asset when our performance under a contract precedes our receipt of consideration from a customer, or before payment is due, and our receipt of consideration is conditional upon factors other than the passage of time. Contract assets reflect our transfer of control of photomasks that are in process or completed but not yet shipped to customers. A receivable is recognized when we have an unconditional right to payment for our performance, which generally occurs when we ship the photomasks. Our contract assets primarily consist of a significant amount of our in-process production orders and fully manufactured photomasks which have not yet shipped, for which we have an enforceable right to collect consideration (including a reasonable profit) in the event the in-process orders are cancelled by customers. On an individual contract basis, we net contract assets with contract liabilities (deferred revenue) for financial reporting purposes. We did not identify impairment indicators for any outstanding contract assets during the three-month periods ended January 28, 2024, or January 29, 2023.


The following table provides information about our contract balances at the balance sheet dates.


Classification
 
January 28,
2024
   
October 31,
2023
 
Contract Assets            
Other current assets
 
$
12,376
    $
10,984
 
                 
Contract Liabilities
               
Accrued liabilities
  $ 8,968
    $ 9,965  
Other liabilities
    11,820
      12,454
 
    $ 20,788     $ 22,419  


The following table presents revenue recognized from contract liabilities that existed at the beginning of the reporting periods.

 
Three Months Ended
 
 
 
January 28,
2024
   
January 29,
2023
 
Revenue recognized from beginning liability
 
$
5,507
   
$
7,638
 


We generally record our accounts receivable at their billed amounts. All outstanding past due customer invoices are reviewed for collectability during, and at the end of, every reporting period. To the extent we believe a loss on the collection of a customer invoice is probable, we record the loss and credit an allowance for credit losses. In the event that an amount is determined to be uncollectible, we charge the allowance for credit losses and derecognize the related receivable. We did not incur any credit losses on our accounts receivable during the three-month periods ended January 28, 2024 or January 29, 2023.


Our invoice terms generally range from net-thirty to ninety days, depending on both the geographic market in which the transaction occurs and our payment agreements with specific customers. In the event that our evaluation of a customer’s business prospects, and financial condition indicate that the customer presents a collectability risk, we modify terms of sale, which may require payment in advance of performance. At the time of adoption, we elected the practical expedient allowed under ASC Topic 606 “Revenue from Contracts with Customers” (“Topic 606”) that permits us not to adjust a contract’s promised amount of consideration to reflect a financing component when the period between when we transfer control of goods or services to customers and when we are paid is one year or less.


In instances when we are paid in advance of our performance, we record a contract liability and, as allowed under the practical expedient in Topic 606, recognize interest expense only if the period between when we receive payment from the customer and the date when we expect to be entitled to the payment is greater than one year. Historically, advance payments we have received from customers have generally not preceded the completion of our performance obligations by more than one year.

Disaggregation of Revenue


The following tables present our revenue for the three-month periods ended January 28, 2024, and January 29, 2023, disaggregated by product type, geographic origin, and timing of recognition.

 
Three Months Ended
 

 
January 28,
2024
   
January 29,
2023
 
Revenue by Product Type
           
IC
           
High-end
 
$
60,875
   
$
48,003
 
Mainstream
   
96,714
     
108,586
 
Total IC
 
$
157,589
   
$
156,589
 
                 
FPD
               
High-end
 
$
50,616
   
$
45,691
 
Mainstream
   
8,129
     
8,810
 
Total FPD
 
$
58,745
   
$
54,501
 
   
$
216,334
   
$
211,090
 

 
Three Months Ended
 

 
January 28,
2024
   
   January 29,
   2023
 
Revenue by Geographic Origin*
           
Taiwan
 
$
74,965
   
$
75,569
 
China
   
58,137
     
58,932
 
Korea
   
40,335
     
37,832
 
United States
   
32,733
     
29,881
 
Europe
   
9,705
     
8,447
 
Other
   
459
     
429
 
   
$
216,334
   
$
211,090
 

* This table disaggregates revenue by the location in which it was earned.

 
Three Months Ended
 
Revenue by Timing of Recognition
 
January 28,
2024
   
   January 29, 2023
 
Over time
 
$
203,527
   
$
197,164
 
At a point in time
   
12,807
     
13,926
 

 
$
216,334
   
$
211,090
 

Contract Costs


We pay commissions to third-party sales agents for certain sales they procure on our behalf. However, the bases of the commissions are the transaction prices of the sales, which are completed in less than one year; thus, no relationship is established with a customer that will result in future business. Therefore, we do not recognize any portion of these sales commissions as costs of obtaining a contract, nor do we currently foresee other circumstances under which we would recognize contract obtainment costs as assets.

Remaining Performance Obligations


As we are typically required to fulfill customer orders within a short period of time, our backlog of orders has historically been two to three weeks for FPD photomasks and one to two weeks for IC photomasks. However, the demand for some IC photomasks has expanded beyond the industrys capacity to supply them within the traditional time period; thus, the backlog, in some cases, can expand to as long as two to three months. As allowed under Topic 606, we have elected not to disclose our remaining performance obligations, which represent the costs associated with the completion of the manufacturing process of in-process photomasks related to contracts that have an original duration of one year or less.

Product Warranties


Our photomasks are sold under warranties that generally range from one to twenty-four months. We warrant that our photomasks conform to customer specifications and will typically repair, replace, or issue a refund for any photomasks that fail to do so. The warranties do not represent separate performance obligations in our revenue contracts. Historically, customer claims under warranties have been immaterial.
v3.24.0.1
SHARE-BASED COMPENSATION
3 Months Ended
Jan. 28, 2024
SHARE-BASED COMPENSATION [Abstract]  
SHARE-BASED COMPENSATION
NOTE 9 - SHARE-BASED COMPENSATION


In March 2016, shareholders approved our current equity incentive compensation plan (the “Plan”), under which incentive stock options, non-qualified stock options, stock grants, stock-based awards, restricted stock, restricted stock units, stock appreciation rights, performance units, performance stock, and other stock or cash awards may be granted. Shares to be issued under the Plan may be authorized and unissued shares, issued shares that have been reacquired by us (in the open market or in private transactions), or a combination thereof. The maximum number of shares of common stock approved that may be issued under the Plan was four million shares. On March 16, 2023, at its annual meeting of shareholders, the shareholders of Photronics, Inc., approved amendments to the Plan to increase the number of shares available for issuance by an additional one million shares, thereby increasing the shares available for issuance under the Plan from four million to five million. Awards may be granted to officers, employees, directors, consultants, advisors, and independent contractors of Photronics or its subsidiaries. In the event of a change in control (as defined in the Plan), the vesting of awards may be accelerated. The Plan, aspects of which are more fully described below, prohibits further awards from being issued under prior plans. The table below presents information on our share-based compensation expenses for the three-month periods ended January 28, 2024, and January 29, 2023.


    Three Months Ended  
   
January 28,
2024
   
January 29,
2023
 
Expense reported in:
           
Cost of goods sold
 
$
595
   
$
281
 
Selling, general, and administrative
   
1,749
     
1,378
 
Research and development
   
229
     
162
 
Total expense incurred
 
$
2,573
   
$
1,821
 
                 
Expense by award type:
               
Restricted stock awards
 
$
2,573
   
$
1,764
 
Stock options
   
-
     
1
 
Employee stock purchase plan
   
-
     
56
 
Total expense incurred
 
$
2,573
   
$
1,821
 
                 
Income tax benefits of share-based compensation
 
$
99
   
$
155
 
Share-based compensation cost capitalized
 
$
-
   
$
-
 



Restricted Stock Awards



We periodically grant restricted stock awards, the restrictions on which typically lapse over a service period of one to four years. The fair value of the awards is determined on the date of grant, based on the closing price of our common stock. The table below presents information on our restricted stock awards for the three-month periods ended January 28, 2024, and January 29, 2023.


   
Three Months Ended
 
   
January 28,
2024
   
January 29,
2023
 
Number of shares granted in period
   
825,050
     
786,500
 
Weighted-average grant-date fair value of awards (in dollars per share)
 
$
29.77
   
$
16.77
 
Compensation cost not yet recognized
 
$
31,426
   
$
18,526
 
Weighted-average amortization period for cost not yet recognized (in years)
   
3.3
     
3.2
 
Shares outstanding at balance sheet date
   
1,634,315
     
1,374,422
 



Stock Options



Option awards generally vest in one to four years and have a ten-year contractual term. All incentive and non-qualified stock option grants must have an exercise price no less than the market value of the underlying common stock on the date of grant. The grant-date fair values of options are based on closing prices of our common stock on the dates of grant and are calculated using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of our common stock. We use historical option exercise behavior and employee termination data to estimate expected term, which represents the period of time that options are expected to remain outstanding. The risk-free rate of return for the estimated term of an option is based on the U.S. Treasury yield curve in effect at the date of grant. The table below presents information on our stock options for the three-month periods ended January 28, 2024, and January 29, 2023.


   
Three Months Ended
 
   
January 28,
2024
   
January 29,
2023
 
Number of options granted in period
   
-
     
-
 
Cash received from options exercised
 
$
936
   
$
563
 
Compensation cost not yet recognized
 
$
-
   
$
-
 
Weighted-average amortization period for cost not yet recognized (in years)
   
-
     
-
 


Information on outstanding and exercisable option awards as of January 28, 2024, is presented below.

Options
 
Shares
   
Weighted-
Average
Exercise
Price
   
Weighted-
Average
Remaining
Contractual
Life (in years)
   
Aggregate
Intrinsic
Value
 
Outstanding and exercisable at January 28, 2024
   
375,525
   
$
10.31
   

2.59
   
$
7,448
 
v3.24.0.1
INCOME TAXES
3 Months Ended
Jan. 28, 2024
INCOME TAXES [Abstract]  
INCOME TAXES
NOTE 10 - INCOME TAXES


We calculate our provision for income taxes at the end of each interim reporting period on the basis of an estimated annual effective tax rate adjusted for tax items that are discrete to each period. The table below sets forth the primary reasons that our effective income tax rates differed from the U.S. statutory tax rates in effect during the three-month periods ended January 28, 2024, and January 29, 2023.

Reporting Period
 
U.S. Statutory
Tax Rates
   
Photronics
Effective Tax
Rates
 
Primary Reasons for Differences

 
   
   
Three months ended January 28, 2024
   
21.0%

   
27.3%

Non-recognition of the tax benefit of losses that, in certain jurisdictions, have been offset by valuation allowances; non-U.S. pre-tax income being taxed at higher statutory rates in non-U.S. jurisdictions; and the establishment of uncertain tax positions in non-U.S. jurisdictions.
                      
Three months ended January 29, 2023
   
21.0%

   
30.3%

Non-recognition of the tax benefit of losses that, in certain jurisdictions, have been offset by valuation allowances; non-U.S. pre-tax income being taxed at higher statutory rates in non-U.S. jurisdictions; and the establishment of uncertain tax positions in non-U.S. jurisdictions.



Uncertain Tax Positions


Although the timing of reversal of uncertain tax positions may be uncertain, as they can be dependent upon the settlement of tax audits, we believe that the amount of uncertain tax positions (including interest and penalties, and net of tax benefits) that may be resolved over the next twelve months is immaterial. Resolution of these uncertain tax positions may result from either or both the lapses of statutes of limitations and tax settlements. We are no longer subject to tax authority examinations in the U.S., major foreign, or state tax jurisdictions for years prior to fiscal year 2018. The table below presents information on our unrecognized tax benefits as of the balance sheet dates.

   
January 28,
2024
   
October 31,
2023
 
Unrecognized tax benefits related to uncertain tax positions
 
$
9,744
   
$
8,908
 
Unrecognized tax benefits that, if recognized, would impact the effective tax rate
 
$
9,744
   
$
8,908
 
Accrued interest and penalties related to uncertain tax positions
 
$
688
   
$
576
 
v3.24.0.1
EARNINGS PER SHARE
3 Months Ended
Jan. 28, 2024
EARNINGS PER SHARE [Abstract]  
EARNINGS PER SHARE
NOTE 11 - EARNINGS PER SHARE


The calculations of basic and diluted earnings per share are presented below.

 
Three Months Ended
 
   
January 28,
2024
   
January 29,
2023
 
Net income attributable to Photronics, Inc. shareholders
 
$
26,180
   
$
13,986
 
Effect of dilutive securities
   
-
     
-
 
Earnings used for diluted earnings per share
 
$
26,180
   
$
13,986
 
                 
Weighted-average common shares computations:
               
Weighted-average common shares used for basic earnings per share
   
61,455
     
60,894
 
Effect of dilutive securities:
               
Share-based payment awards
   
828
     
576
 
Potentially dilutive common shares
   
828
     
576
 
                 
Weighted-average common shares used for diluted earnings per share
   
62,283
     
61,470
 
                 
Basic earnings per share
 
$
0.43
   
$
0.23
 
Diluted earnings per share
 
$
0.42
   
$
0.23
 


The table below illustrates the outstanding weighted-average share-based payment awards that were excluded from the calculation of diluted earnings per share because their exercise price exceeded the average market value of the common shares for the period or, under application of the treasury stock method, they were otherwise determined to be antidilutive.

 
Three Months Ended
 
   
January 28,
2024
   
January 29,
2023
 
Share-based payment awards
   
241
     
268
 
Total potentially dilutive shares excluded
   
241
     
268
 
v3.24.0.1
COMMITMENTS AND CONTINGENCIES
3 Months Ended
Jan. 28, 2024
COMMITMENTS AND CONTINGENCIES [Abstract]  
COMMITMENTS AND CONTINGENCIES
NOTE 12 - COMMITMENTS AND CONTINGENCIES


As of January 28, 2024, we had commitments outstanding for capital expenditures of approximately $142.2 million, primarily for purchases of high-end equipment.


In May 2022, we were informed of a customs audit in one of our China operations. We estimated a contingency ranging from $2.2 million to $3.7 million, which included unpaid additional customs duties and related interest and penalties for the previous three years (the period under audit). In the three-month period ended May 1, 2022, we recorded a contingent loss of $2.2 million, as we believed this was the most likely outcome. The $2.2 million amount was recorded with a charge to Cost of goods sold in the condensed consolidated statements of income and Accrued liabilities in the condensed consolidated balance sheets. In November 2022, upon settlement of the audit, we reversed $1.0 million of the accrual.


We are subject to various other claims that arise in the ordinary course of business. We believe that our potential liability under such claims, individually or in the aggregate, will not have a material effect on our consolidated financial statements.
v3.24.0.1
CHANGES IN ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME BY COMPONENT
3 Months Ended
Jan. 28, 2024
CHANGES IN ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME BY COMPONENT [Abstract]  
CHANGES IN ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME BY COMPONENT
NOTE 13 - CHANGES IN ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME BY COMPONENT


The following tables set forth the changes in our accumulated other comprehensive (loss) income by component (net of tax of $0) for the three-month periods ended January 28, 2024, and January 29, 2023.

 
Three Months Ended January 28, 2024
 
   
Foreign Currency
Translation
Adjustments
   
Other
   
Total
 
                   
Balance at October 31, 2023
 
$
(88,044
)
 
$
(690
)
 
$
(88,734
)
Other comprehensive (loss) income
   
31,493
     
(27
)
   
31,466
 
Other comprehensive (loss) income attributable to noncontrolling interests
   
(10,609
)
   
14
     
(10,595
)
                         
Balance at January 28, 2024
 
$
(67,160
)
 
$
(703
)
 
$
(67,863
)


 
Three Months Ended January 29, 2023
 
   
Foreign Currency
Translation
Adjustments
   
Other
   
Total
 
                   
Balance at October 31, 2022
 
$
(97,790
)
 
$
(666
)
 
$
(98,456
)
Other comprehensive (loss) income
   
90,519
     
(54
)
   
90,465
 
Other comprehensive (loss) income attributable to noncontrolling interests
   
(16,466
)
   
37
     
(16,429
)
                         
Balance at January 29, 2023
 
$
(23,737
)
 
$
(683
)
 
$
(24,420
)
v3.24.0.1
FAIR VALUE MEASUREMENTS
3 Months Ended
Jan. 28, 2024
FAIR VALUE MEASUREMENTS [Abstract]  
FAIR VALUE MEASUREMENTS
NOTE 14 - FAIR VALUE MEASUREMENTS


The accounting framework for determining fair value includes a hierarchy for ranking the quality and reliability of the information used to measure fair value, which enables the reader of the financial statements to assess the inputs used to develop those measurements. The fair value hierarchy consists of three tiers as follows: Level 1, defined as quoted market prices (unadjusted) in active markets for identical securities; Level 2, defined as inputs other than Level 1 that are observable, either directly or indirectly; and Level 3, defined as unobservable inputs that are not corroborated by market data.


The fair values of our cash and certain cash equivalents (Level 1 measurements), accounts receivable, accounts payable, and certain other current assets and current liabilities (Level 2 measurements) approximate their carrying values due to their short-term maturities. The fair values of our Short-term investments are Level 1 measurements. (Please refer to “Investments” within Note 3 for additional fair value information on our Short-term investments.) The fair values of certain cash equivalents are Level 2 measurements that are provided by independent third-party pricing services or other independent entities, which may use matrix pricing, valuation models, or other methods which utilize observable market data. The fair values of our variable-rate debt instruments are Level 2 measurements and approximate their carrying values due to the variable nature of their underlying interest rates. Other than our Short-term investments, we did not have any assets or liabilities measured at fair value, on a recurring or a nonrecurring basis, at January 28, 2024, or October 31, 2023.
v3.24.0.1
SHARE REPURCHASE PROGRAMS
3 Months Ended
Jan. 28, 2024
SHARE REPURCHASE PROGRAMS [Abstract]  
SHARE REPURCHASE PROGRAMS
NOTE 15 - SHARE REPURCHASE PROGRAMS


In September 2020, the Company’s board of directors authorized the repurchase of up to $100 million of its common stock, pursuant to a repurchase plan under Rule 10b5-1 of the Securities Act. The most recent 10b5-1 plan expired on September 15, 2022, and has not been renewed. Share repurchases under this authorization commenced on September 16, 2020. The repurchase authorization by the Board of Directors has no expiration date, does not obligate us to acquire any common stock, and is subject to market conditions. There have been no shares repurchased for the three-month periods ended January 28, 2024, and January 29, 2023. As of January 28, 2024, $31.7 million was available under this authorization for the purchase of additional shares. All shares repurchased under the program have been retired.
v3.24.0.1
RECENT ACCOUNTING PRONOUNCEMENTS
3 Months Ended
Jan. 28, 2024
RECENT ACCOUNTING PRONOUNCEMENTS [Abstract]  
RECENT ACCOUNTING PRONOUNCEMENTS
NOTE 16 - RECENT ACCOUNTING PRONOUNCEMENTS


Accounting Standards Updates to be Adopted



In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”, to enhance the transparency and decision usefulness of income tax disclosures. The amendments in this update related to the rate reconciliation and income taxes paid disclosures to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. The amendments allow investors to better assess, in their capital allocation decisions, how an entity’s worldwide operations and related tax risks and tax planning and operational opportunities affect its income tax rate and prospects for future cash flows. The guidance in this update will be effective for Photronics in its fiscal year 2026 Form 10-K, with early application of the amendments allowed. We are currently evaluating the effect the adoption of this ASU may have on our disclosures.


In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures”, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance in this update is effective for Photronics in its fiscal year 2025 Form 10-K, with early adoption permitted. We are currently evaluating the effect the adoption of this ASU may have on our disclosures.
v3.24.0.1
Insider Trading Arrangements
3 Months Ended
Jan. 28, 2024
shares
Insider Trading Arrangements [Line Items]  
Material Terms of Trading Arrangement On January 11, 2024, Lucien Bouchard, our Vice President of Global Sales and Global Sales Engineering, adopted a Rule 10b5-1 trading arrangement, (the “Plan”) providing for the sale of an aggregate of up to 9,000 shares of our common stock granted to Mr. Bouchard under our compensation program. The Plan is intended to satisfy the affirmative defense in Rule 10b5-1(c). The first date that sales of any shares are permitted to be sold under the Plan was February 12, 2024. All shares under the Plan have been traded.
Name Lucien Bouchard
Title Vice President
Rule 10b5-1 Arrangement Adopted true
Non-Rule 10b5-1 Arrangement Adopted false
Adoption Date January 11, 2024
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
Arrangement Duration 32 days
Aggregate Available 9,000
v3.24.0.1
BASIS OF FINANCIAL STATEMENT PRESENTATION (Policies)
3 Months Ended
Jan. 28, 2024
BASIS OF FINANCIAL STATEMENT PRESENTATION [Abstract]  
Consolidation

The accompanying unaudited condensed consolidated financial statements (“the financial statements”) have been prepared in accordance with U.S. GAAP for interim financial information, and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for annual financial statements. In the opinion of management, adjustments, all of which are of a normal recurring nature, considered necessary for a fair presentation have been included. The financial statements include the accounts of Photronics, its wholly owned subsidiaries, and the majority-owned subsidiaries, which it controls. All intercompany balances and transactions have been eliminated in consolidation. These financial statements should be read in conjunction with the consolidated financial statements and accompanying notes included in our Form 10-K for the fiscal year ended October 31, 2023, where we discuss and provide additional information about our accounting policies and the methods and assumptions used in our estimates.
Estimates and Assumptions

The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect amounts reported in them. Our estimates are based on historical experience and on various assumptions that we believe to be reasonable under the facts and circumstances at the time they are made. Subsequent actual results may differ from such estimates. We review these estimates periodically and reflect any effects of revisions in the period in which they are determined.
v3.24.0.1
INVENTORIES (Policies)
3 Months Ended
Jan. 28, 2024
INVENTORIES [Abstract]  
Inventories Inventories are stated at the lower of cost, determined under the first-in, first-out (“FIFO”) method, or net realizable value.
v3.24.0.1
PDMCX JOINT VENTURE (Policies)
3 Months Ended
Jan. 28, 2024
PDMCX JOINT VENTURE [Abstract]  
Variable Interest Entities

As required by the guidance in Topic 810 - “Consolidation” of the Accounting Standards Codification (“ASC”), we evaluated our involvement in PDMCX for the purpose of determining whether we should consolidate its results in our financial statements. The initial step of our evaluation was to determine whether PDMCX was a variable interest entity (“VIE”). Due to its lack of sufficient equity at risk to finance its activities without additional subordinated financial support, we determined that it was a VIE. Having made this determination, we then assessed whether we were the primary beneficiary of the VIE and concluded that we were the primary beneficiary during the current and prior year reporting periods; thus, as required, the PDMCX financial results have been consolidated with Photronics. Our conclusion was based on the facts that we held a controlling financial interest in PDMCX (which resulted from our having the power to direct the activities that most significantly impacted its economic performance) and had the obligation to absorb losses and the right to receive benefits that could potentially be significant to PDMCX. Our conclusions that we had the power to direct the activities that most significantly affected the economic performance of PDMCX during the current and prior year reporting periods were based on our right to appoint the majority of its board of directors, which has, among others, the powers to manage the business (through its rights to appoint and evaluate PDMCX’s management), incur indebtedness, enter into agreements and commitments, and acquire and dispose of PDMCX’s assets. In addition, as a result of the 50.01% variable interest we held during the current and prior year periods, we had the obligation to absorb losses, and the right to receive benefits, that could potentially be significant to PDMCX.
v3.24.0.1
REVENUE (Policies)
3 Months Ended
Jan. 28, 2024
REVENUE [Abstract]  
Revenue

We recognize revenue when, or as, control of a good or service transfers to a customer, in an amount that reflects the consideration to which we expect to be entitled in exchange for transferring those goods or services. We account for an arrangement as a revenue contract when each party has approved and is committed to perform under the contract, the rights of the contracting parties regarding the goods or services to be transferred and the payment terms are identifiable, the arrangement has commercial substance, and collection of consideration is probable. Substantially all of our revenue comes from the sales of photomasks. We typically contract with our customers to sell sets of photomasks, which are comprised of multiple layers, the predominance of which we invoice as they ship to customers. As the photomasks are manufactured to customer specifications, they have no alternative use to us and, as our contracts generally provide us with the right to payment for work completed to date, we recognize revenue as we perform, or “over time”, on most of our contracts. We measure our performance to date using an input method, which is based on our estimated costs to complete the various manufacturing phases of a photomask. At the end of a reporting period, there are a number of uncompleted revenue contracts on which we have performed; for any such contracts under which we are entitled to be compensated for our costs incurred plus a reasonable profit, we recognize revenue and a corresponding contract asset for such performance. We account for shipping and handling activities that we perform after a customer obtains control of a good as being activities to fulfill our promise to transfer the good to the customer, rather than as promised services, or performance obligations, under the contract. We report our revenue net of any sales or similar taxes we collect on behalf of government entities.


As stated above, photomasks are manufactured to customer specifications in accordance with their proprietary designs; thus, they are individually unique. Due to their uniqueness and other factors, their transaction prices are individually established through negotiations with customers; consequently, our photomasks do not have standard or “list” prices. The transaction prices of the vast majority of our revenue contracts include only fixed amounts of consideration. In certain instances, such as when we offer a customer an early payment discount, an estimate of variable consideration would be included in the transaction price, but only to the extent that a significant reversal of revenue would not occur when the uncertainty related to the variability was resolved.

Contract Assets, Contract Liabilities, and Accounts Receivable

We recognize a contract asset when our performance under a contract precedes our receipt of consideration from a customer, or before payment is due, and our receipt of consideration is conditional upon factors other than the passage of time. Contract assets reflect our transfer of control of photomasks that are in process or completed but not yet shipped to customers. A receivable is recognized when we have an unconditional right to payment for our performance, which generally occurs when we ship the photomasks. Our contract assets primarily consist of a significant amount of our in-process production orders and fully manufactured photomasks which have not yet shipped, for which we have an enforceable right to collect consideration (including a reasonable profit) in the event the in-process orders are cancelled by customers. On an individual contract basis, we net contract assets with contract liabilities (deferred revenue) for financial reporting purposes. We did not identify impairment indicators for any outstanding contract assets during the three-month periods ended January 28, 2024, or January 29, 2023.


We generally record our accounts receivable at their billed amounts. All outstanding past due customer invoices are reviewed for collectability during, and at the end of, every reporting period. To the extent we believe a loss on the collection of a customer invoice is probable, we record the loss and credit an allowance for credit losses. In the event that an amount is determined to be uncollectible, we charge the allowance for credit losses and derecognize the related receivable. We did not incur any credit losses on our accounts receivable during the three-month periods ended January 28, 2024 or January 29, 2023.


Our invoice terms generally range from net-thirty to ninety days, depending on both the geographic market in which the transaction occurs and our payment agreements with specific customers. In the event that our evaluation of a customer’s business prospects, and financial condition indicate that the customer presents a collectability risk, we modify terms of sale, which may require payment in advance of performance. At the time of adoption, we elected the practical expedient allowed under ASC Topic 606 “Revenue from Contracts with Customers” (“Topic 606”) that permits us not to adjust a contract’s promised amount of consideration to reflect a financing component when the period between when we transfer control of goods or services to customers and when we are paid is one year or less.


In instances when we are paid in advance of our performance, we record a contract liability and, as allowed under the practical expedient in Topic 606, recognize interest expense only if the period between when we receive payment from the customer and the date when we expect to be entitled to the payment is greater than one year. Historically, advance payments we have received from customers have generally not preceded the completion of our performance obligations by more than one year.
v3.24.0.1
SHARE-BASED COMPENSATION (Policies)
3 Months Ended
Jan. 28, 2024
Restricted Stock [Member]  
Stock Options [Abstract]  
Share-Based Compensation

Restricted Stock Awards


We periodically grant restricted stock awards, the restrictions on which typically lapse over a service period of one to four years. The fair value of the awards is determined on the date of grant, based on the closing price of our common stock.
Employee Stock Option [Member]  
Stock Options [Abstract]  
Share-Based Compensation

Stock Options



Option awards generally vest in one to four years and have a ten-year contractual term. All incentive and non-qualified stock option grants must have an exercise price no less than the market value of the underlying common stock on the date of grant. The grant-date fair values of options are based on closing prices of our common stock on the dates of grant and are calculated using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of our common stock. We use historical option exercise behavior and employee termination data to estimate expected term, which represents the period of time that options are expected to remain outstanding. The risk-free rate of return for the estimated term of an option is based on the U.S. Treasury yield curve in effect at the date of grant. The table below presents information on our stock options for the three-month periods ended January 28, 2024, and January 29, 2023.
v3.24.0.1
INCOME TAXES (Policies)
3 Months Ended
Jan. 28, 2024
INCOME TAXES [Abstract]  
Income Taxes

We calculate our provision for income taxes at the end of each interim reporting period on the basis of an estimated annual effective tax rate adjusted for tax items that are discrete to each period. The table below sets forth the primary reasons that our effective income tax rates differed from the U.S. statutory tax rates in effect during the three-month periods ended January 28, 2024, and January 29, 2023.
v3.24.0.1
FAIR VALUE MEASUREMENTS (Policies)
3 Months Ended
Jan. 28, 2024
FAIR VALUE MEASUREMENTS [Abstract]  
Fair Value Financial Instruments

The accounting framework for determining fair value includes a hierarchy for ranking the quality and reliability of the information used to measure fair value, which enables the reader of the financial statements to assess the inputs used to develop those measurements. The fair value hierarchy consists of three tiers as follows: Level 1, defined as quoted market prices (unadjusted) in active markets for identical securities; Level 2, defined as inputs other than Level 1 that are observable, either directly or indirectly; and Level 3, defined as unobservable inputs that are not corroborated by market data.
v3.24.0.1
RECENT ACCOUNTING PRONOUNCEMENTS (Policies)
3 Months Ended
Jan. 28, 2024
RECENT ACCOUNTING PRONOUNCEMENTS [Abstract]  
Recent Accounting Pronouncements

Accounting Standards Updates to be Adopted



In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”, to enhance the transparency and decision usefulness of income tax disclosures. The amendments in this update related to the rate reconciliation and income taxes paid disclosures to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. The amendments allow investors to better assess, in their capital allocation decisions, how an entity’s worldwide operations and related tax risks and tax planning and operational opportunities affect its income tax rate and prospects for future cash flows. The guidance in this update will be effective for Photronics in its fiscal year 2026 Form 10-K, with early application of the amendments allowed. We are currently evaluating the effect the adoption of this ASU may have on our disclosures.


In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures”, which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance in this update is effective for Photronics in its fiscal year 2025 Form 10-K, with early adoption permitted. We are currently evaluating the effect the adoption of this ASU may have on our disclosures.
v3.24.0.1
ACCOUNT RECEIVABLES (Tables)
3 Months Ended
Jan. 28, 2024
ACCOUNT RECEIVABLES [Abstract]  
Accounts Receivable
The components of Accounts Receivable at the balance sheet dates are presented below.
 
 
 
January 28,
   
October 31,
 
 
 
2024
   
2023
 
Accounts Receivable
 
$
176,146
   
$
171,433
 
Unbilled Receivable
   
28,551
     
24,593
 
Allowance for Credit Losses
   
(1,090
)
   
(1,099
)
 
 
$
203,607
   
$
194,927
 
v3.24.0.1
SHORT-TERM INVESTMENTS (Tables)
3 Months Ended
Jan. 28, 2024
SHORT-TERM INVESTMENTS [Abstract]  
Available-for-Sale Debt Securities The table below provides information on our available-for-sale debt securities.


   
January 28, 2024
   
October 31, 2023
 
   
Amortized
Cost
   
Unrealized
Gains
   
Unrealized
Losses
   
Carrying
Value
   
Amortized
Cost
   
Unrealized
Gains
   
Unrealized
Losses
   
Carrying
Value
 
Government securities
 
$
12,994
   
$
3
   
$
(1
)
 
$
12,996
   
$
12,913
   
$
4
   
$
(2
)
 
$
12,915
 
v3.24.0.1
INVENTORIES (Tables)
3 Months Ended
Jan. 28, 2024
INVENTORIES [Abstract]  
Inventories

Inventories are stated at the lower of cost, determined under the first-in, first-out (“FIFO”) method, or net realizable value. Presented below are the components of Inventories at the balance sheet dates.

 
January 28,
2024
   
October 31,
2023
 
Raw materials
 
$
49,669
   
$
48,948
 
Work in process
   
1,000
     
1,010
 
Finished goods
   
11
     
5
 
   
$
50,680
   
$
49,963
 
v3.24.0.1
PROPERTY, PLANT, AND EQUIPMENT, NET (Tables)
3 Months Ended
Jan. 28, 2024
PROPERTY, PLANT, AND EQUIPMENT, NET [Abstract]  
Components of Property, Plant and Equipment, Net

Presented below are the components of Property, plant, and equipment, net at the balance sheet dates.


 
January 28,
2024
   
October 31,
2023
 
Land
 
$
11,537
   
$
11,378
 
Buildings and improvements
   
189,152
     
185,850
 
Machinery and equipment
   
1,968,318
     
1,922,041
 
Leasehold improvements
   
19,572
     
18,894
 
Furniture, fixtures, and office equipment
   
16,985
     
15,856
 
Construction in progress
   
84,356
     
55,434
 
     
2,289,920
     
2,209,453
 
Accumulated depreciation and amortization
   
(1,547,249
)
   
(1,500,209
)
   
$
742,671
   
$
709,244
 
Information on ROU Assets from Finance Leases

Information on ROU assets resulting from finance leases, at the balance sheet dates, is presented below.

 
 
January 28,
2024
   
October 31,
2023
 
Machinery and equipment
 
$
42,817
   
$
42,820
 
Accumulated amortization
   
(8,351
)
   
(7,655
)
 
 
$
34,466
   
$
35,165
 
Depreciation Expense

The following table presents depreciation expense (including the amortization of ROU assets) related to property, plant, and equipment incurred during the reporting periods.

 
Three Months Ended
 
 
January 28,
2024
 
January 29,
2023
 
Depreciation Expense   $ 20,605     $ 19,028  
v3.24.0.1
PDMCX JOINT VENTURE (Tables)
3 Months Ended
Jan. 28, 2024
PDMCX JOINT VENTURE [Abstract]  
Net Income (Loss) Recorded from Operations

The following table presents net income we recorded from the operations of PDMCX during the reporting periods.

   
Three Months Ended
 

 
January 28,
2024
   
January 29,
2023
 
Net income from PDMCX
 
$
6,463
   
$
5,918
 
Carrying Amounts and Exposure to Loss Related to Assets and Liabilities

The following table presents the carrying amounts of PDMCX assets and liabilities included in our condensed consolidated balance sheets. General creditors of PDMCX do not have recourse to the assets of Photronics (other than the net assets of PDMCX); therefore, our maximum exposure to loss from PDMCX is our interest in the carrying amount of the net assets of the joint venture.


 
January 28,
2024
   
October 31,
2023
 
Classification
 
Carrying
Amount
   
Photronics
Interest
   
Carrying
Amount
   
Photronics
Interest
 
Current assets
 
$
143,250
   
$
71,639
   
$
135,960
   
$
67,994
 
Noncurrent assets
   
150,077
     
75,054
     
136,334
     
68,181
 
Total assets
   
293,327
     
146,693
     
272,294
     
136,175
 
                                 
Current liabilities
   
36,661
     
18,334
     
36,305
     
18,156
 
Noncurrent liabilities
   
1,929
     
965
     
1,873
     
937
 
Total liabilities
   
38,590
     
19,299
     
38,178
     
19,093
 
                                 
Net assets
 
$
254,737
   
$
127,394
   
$
234,116
   
$
117,082
 
v3.24.0.1
DEBT (Tables)
3 Months Ended
Jan. 28, 2024
DEBT [Abstract]  
Long-term Debt

As of January 28, 2024, the Current portion of long-term debt and the Long-term debt balances were comprised of finance leases as described below:

As of January 28, 2024
 
Finance
Leases
 
Principal due:
     
Next 12 months
 
$
20,771
 
Months 13 – 24
 
$
2,632
 
Months 25 – 36
   
12
 
Months 37 – 48
   
11
 
Months 49 – 60
    -  
Long-term debt
   
2,655
 
Total debt
  $ 23,426  
 
       
Interest rate at balance sheet date
    N/A
 
Basis spread on interest rates
   
N/A
 
Interest rate reset
   
N/A
 
Maturity date
    N/A
 
Periodic payment amount     Varies as Lease mature  
Periodic payment frequency
 
Monthly
 
Loan collateral (carrying amount)
 
$
34,466
(1) 

 
(1)
Represents the carrying amount at the balance sheet date of the related ROU assets, in which the lessors have secured interests.


The table below provides information on our long-term debt as of October 31, 2023.

As of October 31, 2023
 
Finance
Leases
 
Principal due:
      
Next 12 months
  $ 6,621  
Months 13 – 24
  $ 17,972  
Months 25 – 36
    12  
Months 37 – 48
    13  
Months 49 – 60
     1
   
Long-term debt
 
17,998  
Total debt
  $ 24,619
 
 
          
Interest rate at balance sheet date
    N/A  
Basis spread on interest rates
    N/A  
Interest rate reset     N/A
 
Maturity date
    N/A
 
Periodic payment amount     Varies as Lease mature  
Periodic payment frequency     Monthly  
Loan collateral (carrying amount)
  $ 35,165 (1)

 
(1)
Represents the carrying amount at the balance sheet date of the related ROU assets, in which the lessors have secured interests.
v3.24.0.1
REVENUE (Tables)
3 Months Ended
Jan. 28, 2024
REVENUE [Abstract]  
Contract Balances

The following table provides information about our contract balances at the balance sheet dates.


Classification
 
January 28,
2024
   
October 31,
2023
 
Contract Assets            
Other current assets
 
$
12,376
    $
10,984
 
                 
Contract Liabilities
               
Accrued liabilities
  $ 8,968
    $ 9,965  
Other liabilities
    11,820
      12,454
 
    $ 20,788     $ 22,419  


The following table presents revenue recognized from contract liabilities that existed at the beginning of the reporting periods.

 
Three Months Ended
 
 
 
January 28,
2024
   
January 29,
2023
 
Revenue recognized from beginning liability
 
$
5,507
   
$
7,638
 
Disaggregation of Revenue

The following tables present our revenue for the three-month periods ended January 28, 2024, and January 29, 2023, disaggregated by product type, geographic origin, and timing of recognition.

 
Three Months Ended
 

 
January 28,
2024
   
January 29,
2023
 
Revenue by Product Type
           
IC
           
High-end
 
$
60,875
   
$
48,003
 
Mainstream
   
96,714
     
108,586
 
Total IC
 
$
157,589
   
$
156,589
 
                 
FPD
               
High-end
 
$
50,616
   
$
45,691
 
Mainstream
   
8,129
     
8,810
 
Total FPD
 
$
58,745
   
$
54,501
 
   
$
216,334
   
$
211,090
 

 
Three Months Ended
 

 
January 28,
2024
   
   January 29,
   2023
 
Revenue by Geographic Origin*
           
Taiwan
 
$
74,965
   
$
75,569
 
China
   
58,137
     
58,932
 
Korea
   
40,335
     
37,832
 
United States
   
32,733
     
29,881
 
Europe
   
9,705
     
8,447
 
Other
   
459
     
429
 
   
$
216,334
   
$
211,090
 

* This table disaggregates revenue by the location in which it was earned.

 
Three Months Ended
 
Revenue by Timing of Recognition
 
January 28,
2024
   
   January 29, 2023
 
Over time
 
$
203,527
   
$
197,164
 
At a point in time
   
12,807
     
13,926
 

 
$
216,334
   
$
211,090
 
v3.24.0.1
SHARE-BASED COMPENSATION (Tables)
3 Months Ended
Jan. 28, 2024
SHARE-BASED COMPENSATION [Abstract]  
Share-based Compensation Expenses The table below presents information on our share-based compensation expenses for the three-month periods ended January 28, 2024, and January 29, 2023.


    Three Months Ended  
   
January 28,
2024
   
January 29,
2023
 
Expense reported in:
           
Cost of goods sold
 
$
595
   
$
281
 
Selling, general, and administrative
   
1,749
     
1,378
 
Research and development
   
229
     
162
 
Total expense incurred
 
$
2,573
   
$
1,821
 
                 
Expense by award type:
               
Restricted stock awards
 
$
2,573
   
$
1,764
 
Stock options
   
-
     
1
 
Employee stock purchase plan
   
-
     
56
 
Total expense incurred
 
$
2,573
   
$
1,821
 
                 
Income tax benefits of share-based compensation
 
$
99
   
$
155
 
Share-based compensation cost capitalized
 
$
-
   
$
-
 
Restricted Stock Awards Activity The table below presents information on our restricted stock awards for the three-month periods ended January 28, 2024, and January 29, 2023.


   
Three Months Ended
 
   
January 28,
2024
   
January 29,
2023
 
Number of shares granted in period
   
825,050
     
786,500
 
Weighted-average grant-date fair value of awards (in dollars per share)
 
$
29.77
   
$
16.77
 
Compensation cost not yet recognized
 
$
31,426
   
$
18,526
 
Weighted-average amortization period for cost not yet recognized (in years)
   
3.3
     
3.2
 
Shares outstanding at balance sheet date
   
1,634,315
     
1,374,422
 
Stock Options Activity The table below presents information on our stock options for the three-month periods ended January 28, 2024, and January 29, 2023.


   
Three Months Ended
 
   
January 28,
2024
   
January 29,
2023
 
Number of options granted in period
   
-
     
-
 
Cash received from options exercised
 
$
936
   
$
563
 
Compensation cost not yet recognized
 
$
-
   
$
-
 
Weighted-average amortization period for cost not yet recognized (in years)
   
-
     
-
 
Information on Outstanding and Exercisable Option

Information on outstanding and exercisable option awards as of January 28, 2024, is presented below.

Options
 
Shares
   
Weighted-
Average
Exercise
Price
   
Weighted-
Average
Remaining
Contractual
Life (in years)
   
Aggregate
Intrinsic
Value
 
Outstanding and exercisable at January 28, 2024
   
375,525
   
$
10.31
   

2.59
   
$
7,448
 
v3.24.0.1
INCOME TAXES (Tables)
3 Months Ended
Jan. 28, 2024
INCOME TAXES [Abstract]  
Reconciliation of Effective Income Tax Rates from U.S. Statutory Tax Rates The table below sets forth the primary reasons that our effective income tax rates differed from the U.S. statutory tax rates in effect during the three-month periods ended January 28, 2024, and January 29, 2023.

Reporting Period
 
U.S. Statutory
Tax Rates
   
Photronics
Effective Tax
Rates
 
Primary Reasons for Differences

 
   
   
Three months ended January 28, 2024
   
21.0%

   
27.3%

Non-recognition of the tax benefit of losses that, in certain jurisdictions, have been offset by valuation allowances; non-U.S. pre-tax income being taxed at higher statutory rates in non-U.S. jurisdictions; and the establishment of uncertain tax positions in non-U.S. jurisdictions.
                      
Three months ended January 29, 2023
   
21.0%

   
30.3%

Non-recognition of the tax benefit of losses that, in certain jurisdictions, have been offset by valuation allowances; non-U.S. pre-tax income being taxed at higher statutory rates in non-U.S. jurisdictions; and the establishment of uncertain tax positions in non-U.S. jurisdictions.
Unrecognized Tax Benefits The table below presents information on our unrecognized tax benefits as of the balance sheet dates.

   
January 28,
2024
   
October 31,
2023
 
Unrecognized tax benefits related to uncertain tax positions
 
$
9,744
   
$
8,908
 
Unrecognized tax benefits that, if recognized, would impact the effective tax rate
 
$
9,744
   
$
8,908
 
Accrued interest and penalties related to uncertain tax positions
 
$
688
   
$
576
 
v3.24.0.1
EARNINGS PER SHARE (Tables)
3 Months Ended
Jan. 28, 2024
EARNINGS PER SHARE [Abstract]  
Calculation of Basic and Diluted Earnings Per Share

The calculations of basic and diluted earnings per share are presented below.

 
Three Months Ended
 
   
January 28,
2024
   
January 29,
2023
 
Net income attributable to Photronics, Inc. shareholders
 
$
26,180
   
$
13,986
 
Effect of dilutive securities
   
-
     
-
 
Earnings used for diluted earnings per share
 
$
26,180
   
$
13,986
 
                 
Weighted-average common shares computations:
               
Weighted-average common shares used for basic earnings per share
   
61,455
     
60,894
 
Effect of dilutive securities:
               
Share-based payment awards
   
828
     
576
 
Potentially dilutive common shares
   
828
     
576
 
                 
Weighted-average common shares used for diluted earnings per share
   
62,283
     
61,470
 
                 
Basic earnings per share
 
$
0.43
   
$
0.23
 
Diluted earnings per share
 
$
0.42
   
$
0.23
 
Outstanding Securities Excluded from Calculation of Diluted Earnings or Loss Per Share

The table below illustrates the outstanding weighted-average share-based payment awards that were excluded from the calculation of diluted earnings per share because their exercise price exceeded the average market value of the common shares for the period or, under application of the treasury stock method, they were otherwise determined to be antidilutive.

 
Three Months Ended
 
   
January 28,
2024
   
January 29,
2023
 
Share-based payment awards
   
241
     
268
 
Total potentially dilutive shares excluded
   
241
     
268
 
v3.24.0.1
CHANGES IN ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME BY COMPONENT (Tables)
3 Months Ended
Jan. 28, 2024
CHANGES IN ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME BY COMPONENT [Abstract]  
Changes in Accumulated Other Comprehensive (Loss) Income by Component

The following tables set forth the changes in our accumulated other comprehensive (loss) income by component (net of tax of $0) for the three-month periods ended January 28, 2024, and January 29, 2023.

 
Three Months Ended January 28, 2024
 
   
Foreign Currency
Translation
Adjustments
   
Other
   
Total
 
                   
Balance at October 31, 2023
 
$
(88,044
)
 
$
(690
)
 
$
(88,734
)
Other comprehensive (loss) income
   
31,493
     
(27
)
   
31,466
 
Other comprehensive (loss) income attributable to noncontrolling interests
   
(10,609
)
   
14
     
(10,595
)
                         
Balance at January 28, 2024
 
$
(67,160
)
 
$
(703
)
 
$
(67,863
)


 
Three Months Ended January 29, 2023
 
   
Foreign Currency
Translation
Adjustments
   
Other
   
Total
 
                   
Balance at October 31, 2022
 
$
(97,790
)
 
$
(666
)
 
$
(98,456
)
Other comprehensive (loss) income
   
90,519
     
(54
)
   
90,465
 
Other comprehensive (loss) income attributable to noncontrolling interests
   
(16,466
)
   
37
     
(16,429
)
                         
Balance at January 29, 2023
 
$
(23,737
)
 
$
(683
)
 
$
(24,420
)
v3.24.0.1
BASIS OF FINANCIAL STATEMENT PRESENTATION (Details)
3 Months Ended
Jan. 28, 2024
Facility
Manufacturing Facilities [Abstract]  
Number of manufacturing facilities 11
Taiwan [Member]  
Manufacturing Facilities [Abstract]  
Number of manufacturing facilities 3
Korea [Member]  
Manufacturing Facilities [Abstract]  
Number of manufacturing facilities 1
China [Member]  
Manufacturing Facilities [Abstract]  
Number of manufacturing facilities 2
United States [Member]  
Manufacturing Facilities [Abstract]  
Number of manufacturing facilities 3
Europe [Member]  
Manufacturing Facilities [Abstract]  
Number of manufacturing facilities 2
v3.24.0.1
ACCOUNT RECEIVABLES (Details) - USD ($)
$ in Thousands
Jan. 28, 2024
Oct. 31, 2023
ACCOUNT RECEIVABLES [Abstract]    
Accounts Receivable $ 176,146 $ 171,433
Unbilled Receivable 28,551 24,593
Allowance for Credit Losses (1,090) (1,099)
Total $ 203,607 $ 194,927
v3.24.0.1
SHORT-TERM INVESTMENTS (Details) - Government securities [Member] - USD ($)
$ in Thousands
Jan. 28, 2024
Oct. 31, 2023
Available-for-sale [Abstract]    
Amortized Cost $ 12,994 $ 12,913
Unrealized Gains 3 4
Unrealized Losses (1) (2)
Carrying Value $ 12,996 $ 12,915
v3.24.0.1
INVENTORIES (Details) - USD ($)
$ in Thousands
Jan. 28, 2024
Oct. 31, 2023
INVENTORIES [Abstract]    
Raw materials $ 49,669 $ 48,948
Work in process 1,000 1,010
Finished goods 11 5
Inventories $ 50,680 $ 49,963
v3.24.0.1
PROPERTY, PLANT, AND EQUIPMENT, NET (Details) - USD ($)
$ in Thousands
3 Months Ended
Jan. 28, 2024
Jan. 29, 2023
Oct. 31, 2023
Property, plant and equipment [Abstract]      
Property, plant and equipment, gross $ 2,289,920   $ 2,209,453
Accumulated depreciation and amortization (1,547,249)   (1,500,209)
Property, plant and equipment, net 742,671   709,244
Finance lease, Right-of-use asset [Abstract]      
Finance lease, right-of-use asset, gross 42,817   42,820
Accumulated amortization (8,351)   (7,655)
Finance lease, right-of-use asset, net 34,466   35,165
Depreciation Expense [Abstract]      
Depreciation Expense 20,605 $ 19,028  
Land [Member]      
Property, plant and equipment [Abstract]      
Property, plant and equipment, gross 11,537   11,378
Buildings and Improvements [Member]      
Property, plant and equipment [Abstract]      
Property, plant and equipment, gross 189,152   185,850
Machinery and Equipment [Member]      
Property, plant and equipment [Abstract]      
Property, plant and equipment, gross 1,968,318   1,922,041
Leasehold Improvements [Member]      
Property, plant and equipment [Abstract]      
Property, plant and equipment, gross 19,572   18,894
Furniture, Fixtures and Office Equipment [Member]      
Property, plant and equipment [Abstract]      
Property, plant and equipment, gross 16,985   15,856
Construction in Progress [Member]      
Property, plant and equipment [Abstract]      
Property, plant and equipment, gross $ 84,356   $ 55,434
v3.24.0.1
PDMCX JOINT VENTURE, VIE (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Jan. 31, 2018
Jan. 28, 2024
Jan. 29, 2023
Oct. 31, 2023
Variable Interest Entity [Abstract]        
Long-term debt   $ 2,655   $ 17,998
Photronics and DNP [Member]        
Variable Interest Entity [Abstract]        
Term from inception after which interest holder may put their interest in the VIE   2 years    
Period before put or purchase option can be exercised   6 months    
Number of business days for obtaining required approvals and clearance for exiting party   3 days    
Net Income (Loss) from Operations [Abstract]        
Net income from PDMCX   $ 6,463 $ 5,918  
Photronics and DNP [Member] | Minimum [Member]        
Variable Interest Entity [Abstract]        
Ownership percentage   20.00%    
PDMCX [Member]        
Variable Interest Entity [Abstract]        
Long-term debt       $ 0
Photronics Interest [Member]        
Variable Interest Entity [Abstract]        
Ownership percentage   50.01%    
DNP [Member]        
Variable Interest Entity [Abstract]        
Ownership percentage 49.99%      
v3.24.0.1
PDMCX JOINT VENTURE, Carrying Amounts of Assets and Liabilities (Details) - USD ($)
$ in Thousands
Jan. 28, 2024
Oct. 31, 2023
Carrying Amounts of Assets and Liabilities [Abstract]    
Current assets $ 807,677 $ 785,450
Total assets 1,582,836 1,526,221
Current liabilities 185,289 185,223
Total liabilities 235,782 250,612
Carrying Amount [Member]    
Carrying Amounts of Assets and Liabilities [Abstract]    
Current assets 143,250 135,960
Noncurrent assets 150,077 136,334
Total assets 293,327 272,294
Current liabilities 36,661 36,305
Noncurrent liabilities 1,929 1,873
Total liabilities 38,590 38,178
Net assets 254,737 234,116
Photronics Interest [Member]    
Carrying Amounts of Assets and Liabilities [Abstract]    
Current assets 71,639 67,994
Noncurrent assets 75,054 68,181
Total assets 146,693 136,175
Current liabilities 18,334 18,156
Noncurrent liabilities 965 937
Total liabilities 19,299 19,093
Net assets $ 127,394 $ 117,082
v3.24.0.1
DEBT, Long-term Debt (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Jan. 28, 2024
Oct. 31, 2023
Long-term Debt [Abstract]    
Long-term debt $ 2,655 $ 17,998
Finance Leases [Member]    
Long Term Debt Maturing In Year One [Abstract]    
Next 12 months 20,771 6,621
Long-term Debt [Abstract]    
Months 13 - 24 2,632 17,972
Months 25 - 36 12 12
Months 37 - 48 11 13
Months 49 - 60 0 1
Long-term debt 2,655 17,998
Total debt $ 23,426 $ 24,619
Periodic payment amount Varies as Lease mature Varies as Lease mature
Periodic payment frequency Monthly Monthly
Loan collateral (carrying amount) [1] $ 34,466 $ 35,165
[1] Represents the carrying amount at the balance sheet date of the related ROU assets, in which the lessors have secured interests.
v3.24.0.1
DEBT, Finance Leases (Details) - USD ($)
$ in Thousands
1 Months Ended
Feb. 28, 2021
Jan. 31, 2021
Jan. 28, 2024
Dec. 31, 2020
$7.2 Million Finance Lease [Member]        
Finance Lease, [Abstract]        
Finance lease contract term     5 years  
Finance lease amount $ 7,200      
Early buyout option to purchase tool $ 2,400      
Finance lease interest implicit rate 1.08%      
$7.2 Million Finance Lease [Member] | Monthly [Member]        
Finance Lease, [Abstract]        
Finance lease monthly payments $ 100      
$35.5 Million Finance Lease [Member]        
Finance Lease, [Abstract]        
Finance lease contract term     5 years  
Finance lease amount       $ 35,500
Early buyout option to purchase tool   $ 14,100    
Finance lease interest implicit rate   1.58%    
$35.5 Million Finance Lease [Member] | First Three Months [Member]        
Finance Lease, [Abstract]        
Finance lease monthly payments   $ 40    
$35.5 Million Finance Lease [Member] | Following Nine Months [Member]        
Finance Lease, [Abstract]        
Finance lease monthly payments   600    
$35.5 Million Finance Lease [Member] | Forty Eight Months [Member]        
Finance Lease, [Abstract]        
Finance lease monthly payments   500    
$35.5 Million Finance Lease [Member] | Minimum [Member]        
Finance Lease, [Abstract]        
Outstanding committed balance for cross default provision   $ 5,000    
v3.24.0.1
DEBT, Xiamen Working Capital Loans (Details) - Xiamen Working Capital Loans [Member]
¥ in Millions, $ in Millions
1 Months Ended 3 Months Ended
Dec. 31, 2022
USD ($)
Dec. 31, 2022
CNY (¥)
Jan. 28, 2024
USD ($)
Nov. 30, 2018
USD ($)
Debt Instruments [Abstract]        
Maximum borrowing capacity       $ 25.0
Expiration date     Jul. 31, 2024  
Repayments of long-term debt $ 3.6 ¥ 25.6    
Amount outstanding     $ 0.0  
v3.24.0.1
DEBT, Corporate Credit Agreement (Details) - Corporate Credit Agreement [Member] - USD ($)
$ in Millions
3 Months Ended
Jan. 28, 2024
Sep. 30, 2018
Debt Instruments [Abstract]    
Term of loan 5 years  
Current borrowing capacity   $ 50
Maximum borrowing capacity   100
Cash limit for dividends, distributions and redemption on equity   $ 50
Amount outstanding $ 0  
v3.24.0.1
REVENUE, Contract Assets, Liabilities and Accounts Receivable (Details) - USD ($)
$ in Thousands
3 Months Ended
Jan. 28, 2024
Jan. 29, 2023
Oct. 31, 2023
Contract with Customer, Asset and Liability [Abstract]      
Impairment of credit losses on accounts receivable $ 0 $ 0  
Credit losses on accounts receivable 0 0  
Contract liabilities 20,788   $ 22,419
Change in Contract with Customer, Liability [Abstract]      
Revenue recognized from beginning liability 5,507 $ 7,638  
Other Current Assets [Member]      
Contract with Customer, Asset and Liability [Abstract]      
Contract assets 12,376   10,984
Accrued Liabilities [Member]      
Contract with Customer, Asset and Liability [Abstract]      
Contract liabilities 8,968   9,965
Other Liabilities [Member]      
Contract with Customer, Asset and Liability [Abstract]      
Contract liabilities $ 11,820   $ 12,454
Minimum [Member]      
Revenue, Performance Obligation [Abstract]      
Product invoice term 30 days    
Product warranty period 1 month    
Maximum [Member]      
Revenue, Performance Obligation [Abstract]      
Product invoice term 90 days    
Product warranty period 24 months    
IC [Member] | Minimum [Member]      
Backlog of Orders [Abstract]      
Customer order, expected satisfaction period 7 days    
Customer order, extended satisfaction period 2 months    
IC [Member] | Maximum [Member]      
Backlog of Orders [Abstract]      
Customer order, expected satisfaction period 14 days    
Customer order, extended satisfaction period 3 months    
FPD [Member] | Minimum [Member]      
Backlog of Orders [Abstract]      
Customer order, expected satisfaction period 14 days    
FPD [Member] | Maximum [Member]      
Backlog of Orders [Abstract]      
Customer order, expected satisfaction period 21 days    
v3.24.0.1
REVENUE, Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended
Jan. 28, 2024
Jan. 29, 2023
Disaggregation of Revenue [Abstract]    
Revenue [1] $ 216,334 $ 211,090
IC [Member]    
Disaggregation of Revenue [Abstract]    
Revenue 157,589 156,589
High-end [Member]    
Disaggregation of Revenue [Abstract]    
Revenue 60,875 48,003
Mainstream [Member]    
Disaggregation of Revenue [Abstract]    
Revenue 96,714 108,586
FPD [Member]    
Disaggregation of Revenue [Abstract]    
Revenue 58,745 54,501
High-end [Member]    
Disaggregation of Revenue [Abstract]    
Revenue 50,616 45,691
Mainstream [Member]    
Disaggregation of Revenue [Abstract]    
Revenue 8,129 8,810
Taiwan [Member]    
Disaggregation of Revenue [Abstract]    
Revenue [1] 74,965 75,569
China [Member]    
Disaggregation of Revenue [Abstract]    
Revenue [1] 58,137 58,932
Korea [Member]    
Disaggregation of Revenue [Abstract]    
Revenue [1] 40,335 37,832
United States [Member]    
Disaggregation of Revenue [Abstract]    
Revenue [1] 32,733 29,881
Europe [Member]    
Disaggregation of Revenue [Abstract]    
Revenue [1] 9,705 8,447
Other [Member]    
Disaggregation of Revenue [Abstract]    
Revenue [1] 459 429
Over Time [Member]    
Disaggregation of Revenue [Abstract]    
Revenue 203,527 197,164
At a Point in Time [Member]    
Disaggregation of Revenue [Abstract]    
Revenue $ 12,807 $ 13,926
[1] This table disaggregates revenue by the location in which it was earned.
v3.24.0.1
SHARE-BASED COMPENSATION (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 16, 2023
Jan. 28, 2024
Jan. 29, 2023
Mar. 15, 2023
Share-based Compensation [Abstract]        
Maximum number of shares of common stock that may be issued (in shares) 5,000,000     4,000,000
Additional shares available for issuance (in shares) 1,000,000      
Expense incurred   $ 2,573 $ 1,821  
Income tax benefits of share-based compensation   99 155  
Share-based compensation cost capitalized   0 0  
Cost of Goods Sold [Member]        
Share-based Compensation [Abstract]        
Expense incurred   595 281  
Selling, General and Administrative [Member]        
Share-based Compensation [Abstract]        
Expense incurred   1,749 1,378  
Research and Development [Member]        
Share-based Compensation [Abstract]        
Expense incurred   229 162  
Restricted Stock [Member]        
Share-based Compensation [Abstract]        
Expense incurred   $ 2,573 $ 1,764  
Restricted Stock [Abstract]        
Number of shares granted in period (in shares)   825,050 786,500  
Weighted-average grant-date fair value of awards (in dollars per share)   $ 29.77 $ 16.77  
Shares outstanding at balance sheet date (in shares)   1,634,315 1,374,422  
Estimated Expenses Not Yet Incurred [Abstract]        
Compensation cost not yet recognized   $ 31,426 $ 18,526  
Weighted-average amortization period for cost not yet recognized (in years)   3 years 3 months 18 days 3 years 2 months 12 days  
Restricted Stock [Member] | Minimum [Member]        
Share-based Compensation [Abstract]        
Award vesting period   1 year    
Restricted Stock [Member] | Maximum [Member]        
Share-based Compensation [Abstract]        
Award vesting period   4 years    
Stock Options [Member]        
Share-based Compensation [Abstract]        
Expense incurred   $ 0 $ 1  
Stock options activity [Abstract]        
Contractual term   10 years    
Number of options granted in period (in shares)   0 0  
Cash received from options exercised   $ 936 $ 563  
Estimated Expenses Not Yet Incurred [Abstract]        
Compensation cost not yet recognized   $ 0 0  
Outstanding and exercisable option awards [Roll Forward]        
Outstanding at end of period (in shares)   375,525    
Exercisable at end of period (in shares)   375,525    
Weighted-Average Exercise Price [Abstract]        
Outstanding at end of period (in dollars per share)   $ 10.31    
Exercisable at end of period (in dollars per share)   $ 10.31    
Weighted-Average Remaining Contractual Life (in years) [Abstract]        
Outstanding at end of period   2 years 7 months 2 days    
Exercisable at end of period   2 years 7 months 2 days    
Aggregate Intrinsic Value [Abstract]        
Outstanding at end of period   $ 7,448    
Exercisable at end of period   $ 7,448    
Stock Options [Member] | Minimum [Member]        
Share-based Compensation [Abstract]        
Award vesting period   1 year    
Stock Options [Member] | Maximum [Member]        
Share-based Compensation [Abstract]        
Award vesting period   4 years    
Employee Stock Purchase Plan [Member]        
Share-based Compensation [Abstract]        
Expense incurred   $ 0 $ 56  
v3.24.0.1
INCOME TAXES (Details) - USD ($)
$ in Thousands
3 Months Ended
Jan. 28, 2024
Jan. 29, 2023
Oct. 31, 2023
Effective Income and Statutory Tax Rates [Abstract]      
U.S. statutory tax rates 21.00% 21.00%  
Effective tax rates 27.30% 30.30%  
Income Tax Examination [Abstract]      
Earliest open tax year 2018    
Unrecognized Tax Benefits [Abstract]      
Unrecognized tax benefits related to uncertain tax positions $ 9,744   $ 8,908
Unrecognized tax benefits that, if recognized, would impact the effective tax rate 9,744   8,908
Accrued interest and penalties related to uncertain tax positions $ 688   $ 576
v3.24.0.1
EARNINGS PER SHARE (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended
Jan. 28, 2024
Jan. 29, 2023
Calculation of Basic and Diluted Earnings Per Share [Abstract]    
Net income attributable to Photronics, Inc. shareholders $ 26,180 $ 13,986
Effect of dilutive securities 0 0
Earnings used for diluted earnings per share $ 26,180 $ 13,986
Weighted-average Common Shares Computations [Abstract]    
Weighted-average common shares used for basic earnings per share (in shares) 61,455 60,894
Effect of Dilutive Securities [Abstract]    
Share-based payment awards (in shares) 828 576
Potentially dilutive common shares (in shares) 828 576
Weighted-average common shares used for diluted earnings per share (in shares) 62,283 61,470
Basic earnings per share (in dollars per share) $ 0.43 $ 0.23
Diluted earnings per share (in dollars per share) $ 0.42 $ 0.23
Antidilutive Securities [Abstract]    
Total potentially dilutive shares excluded (in shares) 241 268
Share-based Payment Awards [Member]    
Antidilutive Securities [Abstract]    
Total potentially dilutive shares excluded (in shares) 241 268
v3.24.0.1
COMMITMENTS AND CONTINGENCIES (Details)
$ in Millions
1 Months Ended 3 Months Ended
Nov. 30, 2022
USD ($)
Jan. 28, 2024
USD ($)
May 01, 2022
USD ($)
Operation
Commitment and Contingencies [Abstract]      
Outstanding commitments for capital expenditure   $ 142.2  
Period of audit   3 years  
Contingency loss recorded     $ 2.2
Reversal of loss contingency accrual $ 1.0    
Minimum [Member]      
Commitment and Contingencies [Abstract]      
Range of estimated contingency loss     2.2
Maximum [Member]      
Commitment and Contingencies [Abstract]      
Range of estimated contingency loss     $ 3.7
China [Member]      
Commitment and Contingencies [Abstract]      
Number of operations | Operation     1
v3.24.0.1
CHANGES IN ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME BY COMPONENT (Details) - USD ($)
$ in Thousands
3 Months Ended
Jan. 28, 2024
Jan. 29, 2023
CHANGES IN ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME BY COMPONENT [Abstract]    
Other comprehensive income, tax $ 0 $ 0
Changes in Accumulated Other Comprehensive Income [Roll Forward]    
Beginning Balance 975,008  
Ending Balance 1,022,956  
Accumulated Other Comprehensive Income [Member]    
Changes in Accumulated Other Comprehensive Income [Roll Forward]    
Beginning Balance (88,734) (98,456)
Ending Balance (67,863) (24,420)
Foreign Currency Translation Adjustments [Member]    
Changes in Accumulated Other Comprehensive Income [Roll Forward]    
Beginning Balance (88,044) (97,790)
Ending Balance (67,160) (23,737)
Other [Member]    
Changes in Accumulated Other Comprehensive Income [Roll Forward]    
Beginning Balance (690) (666)
Ending Balance (703) (683)
AOCI Including Portion Attributable to Noncontrolling Interest [Member]    
Changes in Accumulated Other Comprehensive Income [Roll Forward]    
Other comprehensive (loss) income 31,466 90,465
Foreign Currency Translation Adjustments [Member]    
Changes in Accumulated Other Comprehensive Income [Roll Forward]    
Other comprehensive (loss) income 31,493 90,519
Other [Member]    
Changes in Accumulated Other Comprehensive Income [Roll Forward]    
Other comprehensive (loss) income (27) (54)
AOCI Attributable to Noncontrolling Interest [Member]    
Changes in Accumulated Other Comprehensive Income [Roll Forward]    
Other comprehensive (loss) income attributable to noncontrolling interests (10,595) (16,429)
Foreign Currency Translation Adjustments [Member]    
Changes in Accumulated Other Comprehensive Income [Roll Forward]    
Other comprehensive (loss) income attributable to noncontrolling interests (10,609) (16,466)
Other [Member]    
Changes in Accumulated Other Comprehensive Income [Roll Forward]    
Other comprehensive (loss) income attributable to noncontrolling interests $ 14 $ 37
v3.24.0.1
FAIR VALUE MEASUREMENTS (Details) - USD ($)
$ in Thousands
Jan. 28, 2024
Oct. 31, 2023
Fair Value, Assets and Liability [Abstract]    
Total assets $ 0 $ 0
Total liabilities $ 0 $ 0
v3.24.0.1
SHARE REPURCHASE PROGRAMS (Details) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended
Jan. 28, 2024
Jan. 29, 2023
Sep. 30, 2020
September 2020 Announced Program [Member]      
Share Repurchase Program [Abstract]      
Stock repurchased authorized amount     $ 100.0
Stock repurchase program - commencement date Sep. 16, 2020    
Amount remaining under authorization for purchase of additional shares $ 31.7    
Share Repurchase Programs [Member]      
Share Repurchase Program [Abstract]      
Number of shares repurchased (in shares) 0 0  

Photronics (NASDAQ:PLAB)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Photronics Charts.
Photronics (NASDAQ:PLAB)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Photronics Charts.